International Pharmaceutical Abstracts 1991: Vol 28 Index

743 Pages·1991·274.9 MB·English

Index to Volume Twenty-Eight
INTERNATIONAL PHARMACEUTICAL ABSTRACTS
January 15, 1991 — June 30, 1991"
2800001 — 2801041 15 Mar 2802500— 2803038 15 May 2804585— 2805154
30 Jan 2801042— 2801568 30 Mar 2803039— 28603453 30 May 2805155— 2805741
15 Feb 2801—5 26801994 5 15 Apr 2803454 — 2803995 15 Jun 2805742 — 2806519
28 Feb 2801946— 2802499 30 Apr 2803996— 2804584 30 Jun CUMULATIVE INDEX
SUBJECT INDEX
A fetamet pivoxil; effects, food, fluid volume, ibuprofen, 2803242; enantiomers
“3902149; oral, liver cirrhosis, 2804980 pharmacokinetics, 2805570; rate constants,
cefetamet sodium; oral, liver cirrhosis, 2804980 sustained-action vs regular, 2803661; skin,
A-64077 cefprozil, comparison, cefaclor; interactions, collagen binding, 2803854
asthma; effects, cold induced bronchoconstriction, food, 2803645; oral, 2803846 implants; salicylic acid release, povidone-
2805246 chloramphenicol; oral, [V blood levels, 2803342; dimethylpolysiloxane matrices, 2800157
rhinitis; effects, allergan induced nasal solid dispersions, 2803662 indomethacin; nanocapsules, blood levels, rats,
congestion, 2805249 ciprofloxacin; GI sites, 2802311 2805353; percutaneous, aqueous gels, vehicle
AACP, see American Association of Colleges of COR-32-24; IV, oral, dogs, 2801849 effects, 2801674; zinc complexes, availability,
Pharmacy cyclosporine; drug interactions, 2805956; 2800143
AB-47; comparison, captopril, enalaprilat, effects, interactions, food, bile acids, availability, insulin; analogs, subcutaneous, 2803139;
in vitro, rats, 2804906 2800131 conjunctiva, dogs, 2801866; nasal, enhancers,
Abbokinase, see Urokinase cyoctol; cutaneous first pass metabolism, 2803843 sheep, 2805968; transport, cornea, mechanisms,
Abbolipid, see Fat emulsions desmopressin; effects, bile salts, rats, 2801296 2801857
Abdominal pain; therapy; pediatrics, 2802227 dextran sulfate; oral, rats, 2806232 insulin human; intranasal, starch microspheres,
Abecarnil dilevalol; review, 2802825 rats, 2804170
phIaVr,m a2c8o0k5in5e8t1i cs; animal species, 2805584; oral, do2c8o0s5a9h8e1x aenoic acid; vehicles, comparisons, iinosmuelignlsa; mifca ctaocris,d ; 2e8f0f5er4v4e8s cence, tablets, 2805363
dopamine; prodrugs, metabolism, dogs, 2802169 iron; complexes, mechanisms, 2802909
Abortifacients
di2n8op0r2o1s1t6; midtrimester, intrafetal injection, ddDooPxs-ya1cg9ye0c 4lf,io nrem2 s8;0h y6co2lr6aa3tl,e ; npoenl-lcertus,s ha2b8l0e0,1 45li st, 2801698 iksepotesocoptrrobroiifdse en ;t herreacptyal,, 2s8u0p1p8os2i3t ory bda-saecst,i on2,8 0a4n7g5i4n a
dinoprost and dinoprostone; ovarian pregnancy,
di2n8o0p1r2o0s1t one and di ovarian p i) y, drr2ua8gts0s,;3 824a82m0;i4 n9oc7pl3ei;npi tciadl asset,ud ieesst, erHaIsVe. axikcintnfieevtciictt:yi ,o nst,i ssues, klleeitudocoticinafeie nne;e; n krieenpvthieaerlwsi,cna ;l e2n8ii0nc5t,r 8a4n28a8 s0a2l,9 12r;at s,s pr2a8y0s3 6v5s6
2801201 methodology, 2805037; equivalency, clinical _nebulizers,S OFTEE
gemeprost; pharmacology, 2805473 studies, methodology, 2805604; exercise effects,
lmiitfiegpartiiosnt;o npea;t ieanbto rtriioghnt s,f ai2l8ur0e2,9 6p4r edictors, 2804997; exercise effects, review, 2803351; lecithin, 2803686; sphingplipals, 801326
food, interactions, 2802151; food variables, lomefloxacin; dosage, 2805568
e2f8f0e1c2ts4,6 ; lacakn,d opvraorsitaang lapnrdeignnsa,n cyt,h er2ap8y0,1 15228;0 11l5a1b;o r d2o8s0a2g7e7 0;f oromrsa,l , 2b8i0o4p1h7a7r;m acneeuwt icoarall fdaocstaogrse, forms, lo2m8e0f3l1o3x1a;c ink idhnyedyr ocfhaliolurried,e ;2 8i0n1t4er3a0c tions, food,
induction, intrauterine fetal death, 2801150; 2805356; percutaneous, in vitro, methodology, loratadine; kidney failure, 2801417
su2lla8pw0rs0o,0s 8tF1orn;ae n;c teet,ro axti2ocg8iet0ny0i,2c 3ic1toy;,n vurlelassceikao,rn csh2,,8 0e2ppo0il0lie9tpi tcis,c U.S., r22e88s00p62i23r91a1t5o;;r y prhetavraircemtwa ,cd oiks2ie8na0se0et1si4,c 0 ;i pnrhsiaknlicanit,pi loenbs,i, o loo2rga8il0c,a6 l2 30; lmoa2rg8an0ze1es8pi6au8mm; ; phefafremcatcs,o kimnienteircasl, suCpNpSl emeefnfteacttsi,o n,
patients, 2803058 factors, 2 preterm infants, 2801414
Abeotirotlioogny; prevention, therapy, 2802829 ei2c8o0s5a9p8e1n taenoic acid; vehicles, comparisons, mmeefdliofqouxianmei;n e;re vioreawl,, 22880065236426
mifepristone; failure, predictors, 2801246 epanolol; geriatrics, 2805583 menadiol sodium diphosphate, comparison,
students; pharmacy, attitudes, 2805680 ephedrine; transdermal patches, 2803142 phytonadione, 2803739
Abruptio placentae; cocaine; abuse, toxicity, erythromycin; food effects, pellets, 2805972 methodology; stable isotopes, 2805038
pregnancy, 2800065 erythropoietin; subcutaneous vs IV injection, methotrexate; interactions, etretinate, 2804744
Absenteeism 255 methylphenidate hydrochloride; enantiomers,
personnel, pharmacy; managed care systems, estradiol; patches transdermal, 2801743; 2801859
costs, 2803486; monitoring systems, 2800375 percutaneous, and metabolism, models, metoclopramide hydrochloride; suppositories,
Absorption 2806292; percutaneous, effects, aging, 2805002 availability, 2805980
abecarnil; animal species, 2805584 estradiol, combination progesterone; nasal, metoprolol fumarate; Oros dosage forms,
acetaminophen, 2803242; gastric emptying rate, effects, dimethyl-B-cyclodextrin, 2805964 2801307
menstrual cycle effects, 2805976; interactions, estrogens conjugated; generic drugs, rates, FDA mexiletine; review, 2806100
atropine, 2802205; poisoning, prevention, attitudes, 2802166 minoxidil; increased, anthralin effects, 2805321;
2803064; rectal, laurocapram enhancement, ethinyl estradiol, combination, norgestrel; keratinocytes, binding sites, kinetics, 2804355;
rabbits, 2803663 interactions, olestra, 2805954 percutaneous, contact time, 2801861;
N-(N-acetyl-L-methionyl)O,O-bis(ethoxycarbonyl) etretinate; interactions, methotrexate, 2804744 percutaneous, radiation induced erythema
dopamine; dogs, 2802169 felodipine; relation, dissolution, methodology, effects, 2806234
albumin; effects, bile salts, rats, 2801296 2801679 moclobemide; kidney failure, 2802338
amifloxacin; oral, 2802893 fentanyl; percutaneous, cadavers, 2806246 models; equal absorption, elimination, 2805026;
4-amino-5-chloro-N-[(1-ethylimidazolin-2-yl)- fenticonazole; topical, blood levels, 2803347 gastrointestinal, in vitro, 2806308; intestinal, rat
methyl]-2-methoxybenzamide; rats, rabbits, fleroxacin; cystic fibrosis, 2802899; infectious jejunum, 2801891; methodology, 2801467;
dogs, monkeys, 2802869 skin diseases, 2802331 semi-simultaneous drug administration,
amoxicillin, combination, clavulanic acid; review, fluconazole, 2806154; CAPD, 2804999; evaluation, 2801892
am2p8h0o2t8e2r4i cin B; intranasal, pediatric, 2800845 ihnytderroaxcitdioen,s , 28a0l4u7m4i0n um hydroxide-magnesium nniacportoixneen;; chinetweirnagct iognusm,s , fooidnt,e rsaucctriaolnfsa,t e,b ev2e8r0a1g2es6,8
anitnit-eirancftliaomnmsa, to2r8y0 4a7g5e0n ts; nonsteroidal, drug fl2u8o0ro2u7r6a0c;i l; trpaenrscduetramnaelo,u sa,l kpyylrcraorlbiadmoonyel vehicles, ni2c8ot0i1n2i6c 9 acid benzyl ester; skin, effects,
an2t8i0ne6o2p0l1a stic agents; chromatography, review, ddiesrtirviabtuitvieosn,, 2r8at0s0,1 4248;0 41w7/3o/ w emulsions, body niefnehdainpciener;s , aviani lvabiivloi,t y,2 80e2q7u5iv5a lency, 2801309
argipressin; skin permeation, iontophoresis, furosemide; activated charcoal effects, 2804159 nitroglycerin; pharmacokinetics, dosage, 2802905;
2801863 gallopamil hydrochloride; availability, film coated skin, animal models, 2803901; transdermal,
as2pi8r0i5n0, 022 803242; percutaneous, effects, aging, tablets, 2803673 aefufteocmtsa,t ed2 80t6e2st4s1, 2803664; transdermal, exercise
bbae2mn8iz0fo4yi4lc2l i1na cei d;h ydpreorcchultoarniedoeu;s , oreaflf,e cctsh,r onaigci ngt,h erapy, ggllayybcbseuorrriipddteeis;o; n ,fe ofof2de8,c 0ts4e,9f f8ep4ch tesn, ollsauclk,f on2p8h0t6h2a5l1e in nnoo2rr8tfr0lio3px8ta5ycl0ii nn;e ; ionrtaelr,a ctsihoonrst, baonwtealc idssy, nd2r8o0m2e1,6 3
bu2p8i0v5a0c0a2i ne hydrochloride; intrapleural, dosage ggousnakanidynol, rcey2ls8it0ne1;i 8ne6a;2n aliontgeusetsi,na l,i onrtatosp,h o2re8s0i3s6,7 1 mouse oofplhotxhaaclimni; c kipdrenpeayr atfaiiolnusr;e , co2r8n0e2a3l,4 0 review,
casfcfheeindeu;l esp,e rc2u8t0a1n8e7o2u s, effects, aging, 2805002 halazepam; pharmacokinetics, 2804385 ox2y8b0e1n4z3o1n;e ;d rvuegh idcelleisv ereyff,e ctrse,v ieswk,in , 28i0n 1v8i7t5ro ,
caelqcuiiuvma;l enccayl,c iu2m8 0c1a2r8b6o;n atdeo saagvaei lasbcihleidtuyl,e sg,e neric he2p8a0r3in8 62s odium; skin, comparison, Hirudoid, pa2f8e0no3l6o7l0; oral, pharmacokinetics, dosage,
models, 2805001 Hirudoid; skin, comparison, heparin sodium, 2806235
caprebdiaamtarziecps,i ne2;8 00s2u0sp0e nsions, seizure therapy, hy2d8r0o3c8or6t2i sone; percutaneous, effects, aging, ppaerpttiicdleess;; qmueamnbtritaanteiso,n, mmoidceel,s ,2 820860219446 3; small,
carprofen; oral, rectal, dogs, 2805963; 2805002; skin, kinetics, vehicles effects, transport parameters, 2806240
suppositories, formulations, 2804761 2803666; skin, penetration enhancers effects, phenolsulfonphthalein; effects, medium chain
cef‘aocoldo,r ,2 8c0o3m6p4a5r;i soorna,l , c2e8fp0r3o8z4il6; interactions, 22880031636086; stratum corneum, effects, fatty acids, gvleyhcicelreisd,e s,2 820820746908 4; percutaneous, pyrrolidone
1215
International Pharmaceutical Abstracts
Absorption Subject Index
phenylephrine; ocular effects, rats, 2802328 triamcinolone absorption, patches transdermal, comparison, beta blockers; B-adrenoceptor
phenylpropanolamine hydrochloride; sustained- 2801680 selectivity, in vitro, 2802202
action, availability, 2805962 alcohols, isopropyl and isopropyl myristate; Acebutolol hydrochloride
phenytoin sodium; interactions, dogs, 2801283; thermodynamics, physostigmine absorption, colorimetry; tablets, 2802294
oral, rectal doses, 2803665 2804758 interactions; a possiole, Kaposi’s
physostigmine; IM, guinea pigs, 2804414; bile salts; rat jejunal membrane, 2804755 sarcoma, 280255
percutaneous, solvents, thermodynamics, dimethyl-B-cyclodextrin; progesterone, estradiol (+)-Acebutolol; = liquid; plasma,
2804758 nasal absorption, 2805964 urine, 2802303
phytonadione, comparison, menadiol sodium drug administration; transdermal, review, (—)-Acebutolol; chromatography, liquid; plasma,
diphosphate, 2803739 2802167 urine, 2802303
pirazolac; pharmacokinetics, 2802917 drugs; skin, fatty acids, amines, 2802753 (+)-Acebutolol, see Acebutolol
polyethylene glycols; enhancers, molecular edetate disodium; rat jejunal membrane, 2804755 R-(+)-Acebutolol, see (+)-Acebutolol
weight, rats, 2805967; nasal, GI, molecular effects; nicotinic acid benzyl ester absorption, S-(—)-Acebutolol, see (—)-Acebutolol
weight, rats, 2806239 skin, in vivo, 2802755; ophthalmic preparations, Acecainide; arrhythmia; therapy, review, 2804859
poly-L-lysine; transport, cornea, mechanisms, review, 2801431; oxybenzone, skin, in vitro, Aceclofenac; pain; therapy, tooth extraction,
2801857 2803670; polyethylene glycols, nasal absorption, dosage, 2803561
polypeptides; oral, 2804168 rats, 2805967; propranolol skin diffusion, Acemetacin; toxicity; SPALA report, 2805230
prednisolone; pharmacokinetics, steroid resistant 2804179; somatropin nasal absorption, 2802754 Acenocoumarin, see Acenocoumarol
asthma, 2802877 1-hexyl-2-pyrrolidone; effects, rat skin, in vitro, Acenocoumarol
procainamide; interactions, sucralfate, 2801277 802757 binding; proteins, structure, 2802911
progesterone; alone and with estradiol, nasal, incompatibilities; transdermal delivery systems, interactions; miokamycin, pharmacokinetics,
2805964 design, 2803675 2805338
propranolol; skin, enhancers, 2804179 isopropyl myristate and alcohols, isopropyl; synthesis; catalysts, 2803764
propranolol hydrochloride; availability, sustained- thermodynamics, physostigmine absorption, Acesulfame-K; review, 2804240
action vs regular, 2804764 2804758 Acetaminophen
dl-propranolol hydrochloride; enantiomers, partial laurocapram; effects, hydrocortisone release, skin, absorption; gastric emptying rate, menstrual cycle
gastrectomy, dogs, 2804985 3668 effects, 2805976; rectal, laurocapram
proxyphylline; pharmacokinetics, 2804418 N-lauryl-2-pyrrolidone; effects, rat skin, in vitro, enhancement, rabbits, 2803663
quinolones; interactions, antacids, 2803644 2802757 abuse; toxicity, myelodyspl synd
ranitidine hydrochloride; film coated vs (+)-limonene; effects, indomethacin gels, 2801135
dispersible tablets, 2803634 computer design, 2801890 alone and with aspirin; effects, PGE 2 synthesis,
roxithromycin; kidney failure, 2802339 lysolecithin; intranasal insulin, sheep, 2805968 2801786
salicylates; soluble dosage forms, 2802171 N-methylpyrrolidone; effects, rat skin, in vitro, blood levels; relation, saliva levels, 2804420
SCH-39304; interactions, antacid, cimetidine, 2802757 chromatography, liquid; plasma, urine, 2803291
2805952 oleic acid; effects, hydrocortisone release, skin, coatings; ethylcellulose, processing variables,
B-sitosterol; polyethylene melt vs regular 2803668; stratum corneum effects, 2804175 803041
capsules, dogs, 2803863 patches transdermal; selection, effects, 2805992 combination, ascorbic acid; tablets, UV, 2803310
skin; models, 2803889; permeation models, salicylic acid; triamcinolone absorption, patches combination, caffeine, ethenzamide; analysis,
2805618 transdermal, 2801680 separation, micellar electrokinetic
somatropin; nasal, enhancers, effects, 2802754 sodium taurocholate; toxicity, mucociliary chromatography, 2801847
steroids, cortico-; pharmacokinetic monitoring, transport velocity, 2804077 combination, codeine; comparison, ketorolac,
05606 sodium taurodihydrofusidate; peptide transport, pain therapy, 2804147
sufentanil; percutaneous, cadavers, 2806246 rats, 2801296 combination, codeine phosphate; rheumatoid
sulfamethoxazole; effects, ascorbic acid, 2803651 starch; insulin microspheres, rats, 2804170 arthritis therapy, pediatrics, 2802807
suilnffaecmteitohno xaprzooplhey,l axciosm,b inraetnailo n,t rantsrpilmaentthaotpiroin,m ; to2p8ic0a3l6 7p9r;e pasrkaitni opnesr;m epartoipoenr,t ies2,8 05s9el7e7c tion, co2m8b0i5n2a3t8io n, oxycodone; concomitant therapy,
2804117; suspensions, in vitro, rabbits, 2801295 toxicity; models, methodology, 2805032 cocmobnicnoamtiitoann,t otxhyecraopdyo,n e2 80hy5d7r9o5c;h lorratiidoen;a l therapy,
surlaftasn,i li2c8 01ac8i5d4; intestinal, immunization effects, tr2a8n0s3de6r5m8a l; delivery systems, development, hospital pharmacy intervention, 2800088
sympatholytic agents; diffusion, intestinal Abuse; drugs, see Drug abuse combination, propoxyphene napsylate; capsules,
epithelium, 2802946 Acacia liquid chromatography, 2800197
talmipnko,n s2; 80l4a6b5el6i ng, FDA regulations, toxic shock cosaytsitnegms;, l2i8t0h2iu7m7,6 gastrointestinal diffusion ccoo2mm8pp0aa5cr2ti3is3oo nn;, maospdierlisn,; tmoexitchiotdy,o loggasyt,r oi2n8te0s5t0i3na5l ,
tteeimcaorpoltaennien;; rfeovoide we,f fe2ct8s0,5 824890 2740 emulsifyyi nogf Maagennatsg;e de ffCecatrse, ePlheactrrmoalyctye;s, 2803164 copmapianr itshoenra,p y,b ro2m8f0e2n0a3c7 sodium; postoperative
te2s8to0s5t0e0ro2n e; percutaneous, effects, aging, Acstaalnydpahrdas ; —phar macisetffse,c tss;u rtvreyyp,a n2oc8i0d3a0l,5 3 leaves, comparison, ibuprofen, indomethacin;
thmeeotphhoyldloilnoeg y,an h2yd8r0o1u8s9;4 ; dofgas tmeod declasn,n ulated dog, Acraatrs,b o2s8e0 2253 cod2my8ps0am2re0in5so0or nr,h eoax intdhearnaapcy;, a2n8t0i3-6e3d3e matous effects,
th2i8a0m1i2n9e3 ;h ydirntoecrhalcotriiodnes,; oErnaslu,r e2,8 0l3a3c4k,9 2805345 colmepvealrsi,s o2n8,0 4m2i8g0l itol; effects, dextrose blood cosmtapblielxiteys,; 2i8n0c5l4u0s1io n, cyclodextrins, humidity,
tiompohltolh almmailce atseo;l utiinotnesr,a ct2i8on0s4,1 62ep;i nesypshtreimniec,, di2a8be0t1e6s1 9m ellitus; non-insulin-dependent, therapy, co2n8c0o1m4i3t5a,n t 28t0he2r0a2p4y,, 22880051815611 , 2801229,
d-o22ac88-u00tl13aor66c,7o6 5p9h ceorntorlo llaecdet atdee;l iveefrfye ctdse,v iLciesn opvhsa remy,e drroaptss,, Acdgcreiruidgaset;nr ticatslo;x icfpia;r tleylvs, e nstuibroovlnei, y , 28h0os4stp6ri7ut1cat !usr,e , 2820800537895 9 ddfiieessvqtesurroi;il vbuuatttlihioeeonnrn ca epr,sya ,tye ss2t;r8e em0vts1ia;2be l9we0,ht o ss,2p i8ti0na2 l1 vi9nt6r o-ein .vi vo 2804623
topical preparations; effects, absorption Accidents; geriatrics; falls, risk factors, Gilbert’s disease; impaired hepatic elimination,
enhancers, 2803679; percutaneous, 2802752; prevention, 2804060 2801758
percutaneous, models, 2805031; skin, Accounting granulations; compressien pressure, tableting,
principles, 2805977 pharmacy; computers, 2806505 04594
transdermal; drug administration systems, review, pharmacy, community; financial analysis, incompatibilities; doxylamine succinate, 2805420
2802167; oleic acid effects, stratum corneum, 2802435; third party collection agency benefits, interactions; atropine, absorption, 2802205;
2804175 2802438 isoniazid, metabolism, toxicity, 2805335;
triamcinolone acetonide; percutaneous, patches Accreditation lamotrigine, pharmacokinetics, 2805951
transdermal, 2801680 clerkships; clinical, curriculum standardization, pain; therapy, 2803242, 2805464
triazolam; interactions, ranitidine, 2800711 need, 2801524 poisoning; therapy, 2803064; toxicity, vomiting,
vadocaine hydrochloride; pharmacokinetics, health care; home infusion therapy, 2805084 2800584
2804422 hospital pharmacy; mock survey, Canada, release; dimethylpolysiloxane elastomer tablet
verapamil; sustained-action vs regular, food 2801973 coatings, 2805403; ethylcellulose coatings,
interactions, 2800147 hospitals; quality assurance vs continuous quality 2803676
verapamil hydrochloride; transdermal, improvement, JCAHO, 2802394 solubilization; effects, antihistamines, 2805378
iontophoresis, 2801419 physicians; pharmacists intervention, DUE data, spheres; cellulose, spheronization kinetics,
verrucarol; IV, oral, dogs, 2802898 2800556 2804211
vitamin A palmitate; effects, Linopharm, rats, residencies; hospital pharmacy, Canada, 2801534 spheronization; kinetics, 2803159; pan vs
2803669 e, see Isotretinoin marumerizer methods, dissolution rates,
VUFB-15468; oral, mice, rats, 2805571 Ac-Di-Sol, see Croscarmellose sodium 2800006
zinc; nutrition, 2803261 Acebutolol sustained-action; duration of action, 2805305;
enhancers chromatography, liquid; dabsylation, 2804941; polymer dispersion, matrix coatings, 2803705
alcohols, ethyi; iontophoresis, polypeptides, enantiomers, plasma, urine, 2802303 therapy; headache, fever, muromonab-CD3
2804757; salicylate permeation, skin, 2801671; chromatography, thin layer; serum, 2802310 toxicity, 2801115
1216 International Pharmaceutical Abstracts
Subject Index Acyclovir
toxicity; anemia, geriatrics, lack, 2804072; gasiric hyperlipidemia; therapy, 2805482 needles; exchange program, APhA, 2802449
ulcers, rats, 2805834; gastrointestinal linoleic acid; mechanisms, cytoprotective effects, new drugs; FDA expedited approvals,
hemorrhage, lack, 2804642; liver failure, 2802843 recommendations, 2802396
prothrombin time, 2803891; liver, G. kola mechanism of action; cytoprotective effects, nutrition; parenteral, therapy, 2805908
protective effects, rats, 2802246 2802842 octreotide; diarrhea therapy, AIDS, 2804259
Acetates; buffers; effects, hydralazine hydrolysis, nomenclature; structure, 2803772; structure, auto- oral manifestations; patient consultation,
2801704 oxidation, 2803284 pharmacists guidelines, 2801376
Acetazolamide vehicles; docosahexaenoic acid availability, pediatrics; diagnosis, therapy, prevention,
ataxia; familial cerebellar, therapy, 2802718 2805981; eicosapentaenoic acid availability, 2804246
dosage forms; oral liquid, formulations, 2804190 2805981 pentamidine; prophylaxis, pregnancy, 2803943;
errors, medication; chlorpropamide dispensed, Acinetobacter species; resistance; ceftazidime, toxicity, pancreatitis, hemophilia, 2803508
2801116 pneumonia, 2803571 pentamidine, comparison, sulfamethoxazole,
interactions; salicylic acid, review, 2801285 Acipimox; and cholestyramine resin; combination, trimethoprim; P. carinii
toxicity; taste disorders, altitude sickness therapy, hyperlipidemia therapy, 2802032 pneumonia, 2800129
2802566 Acitretin pentamidine isethionate; aerosol distribution,
Acetic acid; combination, copper acetate, honey; and radiation, ultraviolet; psoriasis therapy, posture effects, 2805556; aerosols,
history, Unguentum Aegyptiacum, 2803952 2802134 environmental toxicity, 2806331; aerosols,
Acetogenins; Anona squamosa; isolation, 2802366 pharmacokinetics; obesity, rats, 2804987 toxicity, asthma, 2805799; aerosols, toxicity,
Acetone Acne diabetes mellitus, 2803522; P. carinii pneumonia
and alcohols, isopropyl; gored ~~ 2803 166; cosmetics; toxicity tests, 2802231 therapy, prophylaxis, 2800079; interactions,
solvents, polymer films, 2803 isotretinoin; therapy, pregnancy prevention amphotericin B, toxicity, 2802162; therapy,
Powe risk management, Hosp, 2802548 programs, FDA regulations, 2801476 adverse reactions, 2805826
"2!- Jp ropoxyacetaCnpiel iwdpee ny see 5’-Nitro- thOeTrCapsy,, 22880043226203; 2r8e0v4i2e3w8, ; 28ad0o4l8e6s3c ents, 2804239; pr2e8d0n5i8s8o9ne;; PP.. ccaarriinniiii ppnneeuummoonniia,a t2h8e0r0a1p0y,3
Acetyl-5-aminosalicylic acid; metabolites; Aconitum tschangbaischanese; constituents; probenecid; therapy, 2805881
mesalamine, pharmacokinetics, 2804747 isolation, identification, 2803879 prophylaxis; transmission, health professions,
L-Acetylcarnitine; depression; therapy, senile Acquired immunodeficiency syndrome 2806333
dementia, 2802624 acetylcysteine; therapy, 2805881 ribavirin and globulin immune; measles therapy,
Acetylcholine acyclovir; herpes zoster therapy, dosage, 2801252
effects; isolated frog heart, 2802855; resistance, 2802075; resistance, varicella-zoster rifampin; combined therapy, Mycobacterium
vasoconstriction, endotoxic rat aorta, 2806124 virus, 2802089 infections, 2801195
Acetylcholine chloride; effects; neurogenic amikacin; combined therapy, Mycobacterium steroids, cortico-; P. carinii pneumonia adjuvant
contractions, guinea pig bronchi, 2801795 infections, 2801195 therapy, 2805888
Acetylcholinesterase; release; liposomes, aminoglycosides; pharmacokinetics, 2800817 sulfadiazine; toxoplasmosis therapy, toxicity,
ophthalmic preparations, in vitro, 2802758 amphotericin B; interactions, pentamidine, crystalluria, 2805218
Acetylcysteine toxicity, 2802162 sulfamethoxazole and trimethoprim; vs dapsone-
acquired immunodeficiency syndrome; therapy, anti-infective agents; home IV therapy, 2800678 trimethoprim, P. carinii pneumonia therapy,
2805881 antivirals; algorithms, 2800656; therapy, research, 2801189
ac hen overdose, 2805335 review, 2803734 sulfamethoxazole, combination, trimethoprim;
atherosclerosis; — 2805872 benzodiazepines; toxicity, respiratory depression, comparison, pentamidine, P. carinii pneumonia,
chromatography, liquid; urine, 2803324 P. carinii pneumonia, 2800572 2800129
effects; somatropin nasal absorption, bleomycin; Kaposi’s sarcoma therapy, cutaneous sulfonamides; desensitization therapy, 2800118
enhancement, 2802754; stability, alanineamino side effects, 2803509 thalidomide; aphthous stomatitis therapy, 2805841
transferring solutions, 2805417 cat-scratch disease; antibiotic therapy, 2801259 therapy; P. carinii pneumonia prophylaxis,
interactions; nitroglycerin, tolerance, 2805949 CD-4; therapy, dosage, 2802044, 2802045 2801736; P. carinii pneumonia, review,
mechanism of action; in vitro, in vivo, 2801799 ciprofloxacin; combined therapy, Mycobacterium 2802814; diagnosis, transmission, 2801378;
prodrugs; synthesis, hydrolysis, 2804779 infections, 2801195 home care, 2803741; new approaches, 2800786;
therapy; acetaminophen poisoning, 2803064; clinical studies; controlled vs open, 2806415; pediatrics, 2805863; research, AIDS conference,
meconium ileus, cystic fibrosis, 2800597 pharmacists role, AIDS Clinical Trials Group, 2803176; research, product development,
N-Acetylcysteine, see Acetylcysteine 2801545 2802239; therapy, 2801638
N-Acetyl-L-cysteine, sce Acetylcysteine cytomegalovirus immune globulin and trimethoprim and dapsone or sulfamethoxazole; P.
Acetylhomotaurine calcium; chromatography, ganciclovir; cytomegalovirus retinitis, 2801266 carinii pneumonia therapy, 2801189
gas; plasma, urine, 2804379 dapsone; P. carinii pneumonia, prophylaxis, vidarabine; herpes zoster therapy, lack, 2802089
3-Acetylmesaconitine; Aconitum 2803600 zidovudine; and AIDS-related complex therapy,
tschangbaischanese; roots, 2803879 dapsone and trimethoprim; vs sulfamethoxazole- survival markers, 2805017; and antivirals, long
N-(N-Acetyl-L-methionyl)O,O- trimethoprim, P. carinii pneumonia therapy, term therapy, non-Hodgkin lymphoma risk,
bis(ethoxycarbony!l) dopamine; prodrugs; 2801189 2801713; dementia therapy, intrathecal,
dopamine, metabolism, dogs, 2802169 didanosine; and AIDS-related complex, therapy, 2802102; history, research and development,
N-Acetylprocainamide, see Acecainide previous zidovudine, 2802028; pancreatitis, risk, 2802422; liver diseases, pharmacokinetics,
Acetylsalicylic acid, see Aspirin NIAID guidelines, 2801987; pharmacokinetics, 2803845; malignancies, pediatrics, 2801236;
N4-Acetylsulfadimethoxine; pharmacokinetics; 2802907; side effects, pancreatitis, 2800577; pharmacokinetics, models, 2801455; reduced
metabolites, 2802336 therapy, 2805429; therapy, myopathy toxicity, dosage, effectiveness, 2801167; therapy, review,
N+-Acetylsulfamethoxazole; chromatography, 2801099; therapy, pancreatitis toxicity, 2801346
liquid; serum, 2802288 2804646; therapy, toxicity, hypokalemia, zidovudine and dideoxycytidine; combined
Aciclovir, see Acyclovir 2805203 therapy, 2805856, 2805857, 2805859
Acid red 87; chromatography, liquid; and xanthine 2' ,3'-dideoxyadenosine; pharmacokinetics, zidovudine and ganciclovir; cytomegalic inclusion
homologs, 2802280 2802907 disease therapy, toxicity, 2801127
Acid-base imbalance; therapy; metabolic, dideoxycytidine; therapy, 2805860, 2805861 Acridiny! anisidide, see Amsacrine
respiratory, 2806150 dideoxycytidine and zidovudine; combined Acrodermatitis; cyclosporine; therapy, review,
Acidifying agents; sodium phosphate monobasic, therapy, 2805856, 2805857, 2805859 2802142
combination, tartaric acid; tablets, saliva disulfiram; therapy, 2805881 Acromegaly
secretion, 2804208 epoetin alfa; anemia therapy, 2801354 bromocriptine; therapy, pregnancy, 2801197
Acidity ethambutol; combined therapy, Mycobacterium octreotide; home therapy, 2800702; therapy,
honey; potentiometry, 2804393 infections, 2801195 administration rates, 2801466
solutions, ophthalmic; buffers, 2804796 fluconazole, comparison, ketoconazole; octreotide acetate; therapy, withdrawal, diabetes
Acidosis candidiasis therapy, 2803114 complications, 2803612
insulin and oral rehydration compound; diabetic, foscarnet sodium; adverse reactions, diabetes Acrylamides; hydrogels; thermosensitive, swelling,
therapy, 2802646 insipidus, 2801093 2802777
oral rehydration compound and insulin; diabetic, ganciclovir; alone and with cytomegalovirus Acrylics; cements; gentamicin release, viscosity,
therapy, 2802646 immune globulin, retinitis, 2801266; therapy, 2805982
terbutaline sulfate; diabetic, toxicity, preterm 2801262 Acteoside; Castilleja linariaefolia; isolation,
labor therapy, 2801112 ganciclovir and zidovudine; cytomegalic inclusion cytotoxic effects, 2802356
therapy; metabolic, respiratory, 2806150 disease therapy, toxicity, 2801127 ACTH, see Cort
Acids; poisoning; symptoms, treatment, 2803066 globulin immune and ribavirin; measles therapy, Actilyse, see Alteplase
Acids, fatty 2801252 Activase, see Alteplase
absorption enhancers; skin, mechanisms, 2802753 influenza vaccines; immunization, 2805921 Activated carbon, see Charcoal activated
arachidonic acid; mechanisms, cytoprotective @ 2,-interferon; Kaposi’s sarcoma therapy, Actrapid H, see Insulin human
effects, 2802843 pediatrics, 2805315 Acutrim, see Phenylpropanolamine
carrot seed oil; analysis, 2803357 ketoconazole, comparison, fluconazole; hydrochloride
effects; hydrocortisone absorption, stratum candidiasis therapy, 2803114 Acyclovir
corneum, 2801306 methylprednisolone; P. carinii pneumonia acquired immunodeficiency syndrome; therapy,
esters; synthesis, 2804936 therapy, 2805890 home care, 2803741
International Pharmaceutical Abstracts
Acyclovir Subject Index
alone and with silicon dioxide; compounding, lip nutrition, incompatibilities, iron dextran, health benefit programs; employers, cost control,
balms, 2804185 2800164; parenteral nutrition, stability, 2801495; patient oe HMO, survey,
chickenpox; therapy, HIV infections, 2802097 containers, 2802189; phenytoin sodium, pH 2801494; trends, 2801493
concomitant therapy, 2801114 2802325 variations, stability, 2806031; phenytoin health care; home, IV infusions, industry,
costs; comparison, gold, 2805932 stability, concentration, 2800730; ranitidine 2806429; laws, Great Britain, 2806353; quality
hepatitis B; therapy, 2806139 incompatibilities, stability, 2800740; ranitidine, assurance vs continuous quality improvement,
herpes genitalis; continuous vs acute therapy, incompatibilities, vehicles, stability, 2800162; JCAHO, 2802394
recurrence, 2805866 ranitidine-TPN incompatibilities, 2800731; health professions; specialties, certification,
herpes simplex; neonatal, prophylaxis, pregnancy, services, hospital pharmacy survey, Montana, 2806387
2802060 2803488; systems evaluation, 2800340; hospital pharmacy; H2 antagonists, formulary
herpes zoster; therapy, dosage, AIDS, 2802075 theophylline incompatibilities, 2800752; TPN, selection, ethics, 2802427; clinical interventions,
incompatibilities; foscarnet, IV injections, compounding, 2804209; TPN, compounding, cost savings, 2802523; clinical interventions,
2800163; morphine, meperidine, IV injections, computer programs, 2804618; TPN, stability, documentation, 2801595; clinical pharmacists,
patient controlled analgesia, 2803722 automated compounding methods, 2805412; hiring or training, 2801066; clinical pharmacy,
interactions; zidovudine, synergism, lack, HIV vancomycin, incompatibilities, methotrexate, department goals, 2800013; computer programs,
infections, 2801166 lack, 2802186; zidovudine, incompatibilities, drug utilization, 2802491; conflict, change,
resistance; varicella-zoster virus, high dose, vehicles, stability, 2804806 2804026; crisis management, 2801970; disaster
AIDS, 2802089 solutions; compounding, computer programs, planning, hurricanes, 2800032, 2801594;
therapy, 2804874 805692 dispensing quotas, 2800026; documentation,
utilization; oral, topical, 2804150 soybean oil; effects, perflunafene emulsion clinical services, computers, 2803449; drug
Acylated plasminogen-streptokinase activator stability, 2801321 utilization review, 2805187; effects, managed
complex, see Anistreplase toxicity; excipients, side effects, 2803539 care systems, 2801588, 2801589, 2801590;
AD-4833, see Pioglitazone Ademetionine employment, pharmacists, drug abuse recovery,
AD-810, see Zonisamide an re intrahepatic, therapy, pregnancy, 2805071; England, purchasing, cost control,
Adagen, see Pegademase bovine 28035 2800261; environmental analysis, methodology,
Adalat, see Nifedipine dadioninns therapy, Parkinson disease, 2802606 2804453; formulary systems, Georgia, survey,
Adalat Retard, see Nifedipine Adenocarcinoma 2800432; health care costs, decision making,
Adcock Ingram; South Africa; ownership, diethylstilbestrol; in utero exposure, 2801142 2805785; hours, women pharmacists, 2803480;
structure, 2804520 steroids, cortico-; endometrial, therapy, 2802713 interdisciplinary quality assurance activities,
Addiction, see Dependence Adenocard, see Adenosine 2801064; inventory management, 2800416,
Addicts Adenoma; danazol; hepatocellular, toxicity, 2800456; IV additives, medication errors,
drug abuse; programs, increased budgets, 2800073 quality assurance, 2802525; Navy ships, Persian
recommendations, 2804490 Adenosine Gulf, 2805188; nontraditional Masters degrees,
vancomycin; S. aureus endocarditis therapy, and thallium-201; pharmacologic stress imaging, 2800937; OSHA standards, hazardous
2802696; pharmacokinetics, 2802332 2805427 substances, 2801475; part time personnel,
Admdeidsiocnat’iso n,d isepaatsiee;n t hyeddruoccaotritoins,o ne2;8 05s6el5f3- eafrfrehcytts;h minae;w tdhreurgasp,y , 19in9j0e,c ti2o8n0s,4 28278 04870 22880001407628;; ppaattiieenntt ccoonntsruolltlaetdi ona,n alqugaelsiitay saesrsvuircaesn,c e,
Additives interactions; xanthines, vasodilation effects, 2802524; peer review, performance, 2800459;
dffelopaoivdlo,ra st,os reies eeseF; ooFpdla;at venoatrdssd,;i ti2av8de0dsi4 t8i8v0es ptah2ca8hr0ymc5aa9cr4od8il ao;g y;p arroexvyisemwa, l 28s0up4r3a4v9e ntricular, dosage, pppehhraasrrommnaancceoolk lionmgeaytn iacgpsre omgesrenartvm,isc ,e sl,ep ghagylus iiidcseislauinen se,sr ,e s2i82d08e2n09c16i08e6s;3, ;
in2j8ec0t1i0o6n1s;; aadmmpihxottuerrei cidnr ugB ,d eilnicvoemrpya tisbyisltietmise,s , t2h8e0r1a7p8y,3 2801624; supraventricular, therapy, q2u8a0l0i0t3y 1;a sspurroadnuccet, lpiantei emnta naimgpeamcetn,t ,2 80218007030;0 9;
deccsabicB2eodneyzlo 8xnucfstem0sttoactro4tpramzaeeam8ioopotmboy0nsaliusinece4tiol,nar,ini;in dsmt b n,y,ii s, slIncu tiVaeghriat2 d2ovfnb i8smeic8oaep0lyio0pedsii,2mxr0em,tt p1rt7r iyaoau8,a2xlrt2r 7 t2z0si8e;,u8o;bp0sp r0n ie4,hele2r 0aclsiia-1ira3t,tmc9amrs3io bsi1tdae;inaam;iclse 2bce ioi,ai8rttp sllay0iailit ,n4nnteds vtty8edgie,i,ii 02ih nn -ai2c8eeilc ;0o22 nylp 48f8sesle0i00soacas346,lst m0 50utip;t33svihi 39oecool ;; ntu setaa,irgg oeeinnncstti,ssn ,, dSAAid-dte-bmpasehhi Aeatteognettderlrncohsneaoashoysdingpieilsiooiylosmicnnes,l ea se y;lt t, ls,h2r -t pa8at-r ac2n0rLestrs8n4ie-cydge02pmh elth17eehrao02tBs,mts h4 iaepi4lo-tch2o;a arha8 ndcaat0ihrnrec4nyesg;o8edlse ms3,eii epr 6coetaem nafras cfilAeahee,scdcy iotecdsnAam ,2,rde 8 cdeti0o2mia21p8eo;87o0 tn0l43iiy13t6onm6 h9nee8e4rir 7 a;n p ey , hocesssr2mUsltpexeo.8parercptS0iracvyai.t2itiicv naf5eacllasigle3istAciiis4n;aiesor,; gtsto nm i,sn,no ,y,U pno t .,r2meS 2go8lis2.e8eg0ne8,pn0prar0 0eh3hval0r3ai4om 1ar14cn8sl99m9ee7ig,;9as8,s;r 0 ,c; to , is u 2rs,crpSo8t otelA a0stemeuS2,4r,atmde 80Hmeuia01 cP tAnt48hsJi eb0,;nAccH ui2 rhsaPiq7anpult,urb;ilrdeeii cavio,aoinenr ,sna2ynggt n8,,i aa2s 0 nfn28,tgf4i0 8 2e,52z10c8 68a20h5090t87n72i;10i657o 91q;n206u9 ,2r 1e6 o;;s7l , e;
incompatibilities, 2803719; cefoperazone- polymers; autohesion, review, 2805398 organizational development, change agents,
furosemide incompatibilities, 2803720; Adhesives 2802985; personnel, time clocks, use, survey,
ceftazidime-aminophylline incompatibilities, biological, see Bioadhesives 2800012; prescribing, computer orders, effects,
2800722; cefuroxime-metronidazole admixtures, labeling; drugs, raw materials, 2805165 pharmacy, 2801081; strategic planning,
stability, 2801338; centralized services, patches transdermal; incompatibilities, permeation diversification, 2801592; supervision, pharmacy
2801078; cisplatin incompatibilities, stability, enhancers, 2803675 5 administrators, 2803495
2800737; clavulanate-ticarcillin, stability, Adibendan; effects; hemodynamics, heart failure, industry; cosmetics, quality control, 2804611;
2805414; clindamycin, stability, 2803723; 2805260 quality control, philosophy, 2803458
compounding training programs, 2800936; Adinazolam mesylate; depression; therapy, industry, pharmaceutical; computer integrated raw
computerized compounding, 2800309; 2801793 material tracking, 2801053; computers, uses,
enalaprilat incompatibilities, 2800729, 2802192, Adipic acid; compaction; models, methodology, India, 2803450; direct to consumer advertising,
2806048; etoposide, flow rates, drop size 2805035 2802984; information management, computers,
effects, 2802172; fat emulsion-iron dextran Aditoprim; analysis; radioassay, pharmacokinetics, 2804615; managers, essential qualities,
incompatibilities, TPN, 2800743; fluorouracil, goats, 2805569 2801913; Sandoz facility expansion, 2805753
spirogermanium, incompatibilities, 2800166; Adjuvants, see Excipients insurance; shared risk, costs, 2801498
foscarnet incompatibilities, 2800163; gentamicin Administration inventory; pharmacy, guidelines, 2805661
stability, IV solution cassettes, 2804223; American Society of Hospital Pharmacists; Public managed care systems; pharmacy services,
haloperidol stability, 2800747; heparin, Information Division, 2801960; strategic personnel, 2803486; trends, hospital pharmacy
incompatibilities, IV admixtures, stability, planning, 1990-91, 2800014 impact, 2801496
2800748; hospital pharmacy, quality assurance, Board of Pharmaceutical Specialties; certification, management; subordinates self-confidence,
guidelines, 2802525; hospital pharmacy 806457 2801507
services, guidelines, 2804633; incompatibilities, clinical pharmacists; job description, hospitals, Manesty Machines; tablet presses, manufacturers,
2800745, 2805424; incompatibilities, ceftriaxone 2801965 2801505
and vancomycin, precipitation, 2804221; clinical studies; computerized data management, manpower; part-time pharmacists, community
incompatibilities, opiates, patient controlled survey, 2806511; in house audits, 2805615; trial pharmacy, 2806468
analgesia, 2803722; incompatibilities, PCA, management organizations, 2806329 Medicaid; health care rationing, Oregon, 2801506
2800750; inservices, 2800510; insulin human committees; ethics, hospital pharmacists role, Medicare; reimbursement, LTCF patients,
incompatibilities, 2803721; insulin 2801509 Pennsylvania, 2801491
incompatibilities, 2800749; intravenous, shelf- drug utilization; review, pharmacists Michigan Pharmacists Association; planning,
life, 2803725; maple syrup urine disease recommendations, prioritizing system, 2805777; 1991, 2806399
therapy, 2800327; methadone, stability, storage, review, programs, Oregon, 2802499 Minnesota State Pharmaceutical Association;
2806033; miconazole-polyviny! chloride drugs, see Drug administration strategic planning, 2803007
incompatibilities, dialysis solutions, 2804805; education, pharmaceutical; continuing, ASHP National Institutes of Health; research problems,
milrinone incompatibilities, 2802188; programs, 2801587; mission statement, AACP, 2806404
mitoxantrone incompatibilities, antineoplastic 2801518; New Zealand, 2805111; social nurses; management, dependent professionals,
agents, 2800744; nizatidine, incompatibilities, influence, pharmacist empowerment, 2801528 2802983
IV admixtures, 2800724; ondansetron financial management; Activase Financial personnel; appraisal systems, 2803956;
incompatibilities, stability, 2800751; parenteral Assistance Program, 2800914 employment, discrimination, laws, England,
1218 International Pharmaceutical Abstracts
Subject Index Aerosols
2800243; pharmacists, chemical dependency, Administration sets, see Surgical supplies; interleukin 18; plastic containers, syringes,
rehabilitation programs, 2802425 administration sets 2804809
personnel, pharmacy; employee motivation, dministrators polymers; complexes, surface active agents,
2800278; manager-employee conflict, resolution, attitudes; dispensing quotas, ama 2800026; 2806026
2800252; technicians, ASHP guidelines, hospital pharmacists, 2800889 proteins; membrane fouling, 2803163
2804629 education; psychiatry, consultant pharmacy pyrogens; charcoal, polyethylene, 2805172
pharmacists; business federation, Hungary, services, long term care facilities, 2805773 Salicylic acid; films, release effects, 2804194
2806482; role, patient outcome, 2801550 health benefit programs; third party, attitudes, spirogermanium hydrochloride; IV containers,
ists, community; group practices, Great pharmaceutical benefits, survey, 2801504 tubing, 2800166
Britain, 2805135 hospital pharmacy; salaries, California, survey, surface a agents; complexes, polymers,
pharmacists, institutional; cost benefit and cost 2806401; salaries, survey, 2805073; supervisors,
effectiveness analyses, 2801969 2803495; VA 1990 Implementation Conference, Adulteration
pharmacy; biotechnology, 2805672; Canada, objectives, 2801958 Arctostaphylos uva-ursi; analysis, 2803367
Northwest Territories, 2805140; computers, — clinical pharmacists value, 2804025 Amica species; by Asteraceae, flavonoid
2801942; cultural awareness needs, 2806432; industry, pharmaceutical; cultural awareness identification, 2806277
decision making, methodology, 2806425; “wale 2806432; essential qualities, 2801913 Artemisia species; morphology, identification,
managing change, 2800475; natural disaster organizations; pharmacy, attitudes, PharmD entry 2803360
preparations, 2806398; pharmacists attitudes, level degree, 2804532 lilicium verum; by I. anisatum, differentiation,
survey, 2805145; specialties, certification pharmacists, hospital; salaries, survey, Georgia, 2805596
procedures, 2806455; trust issues, staff 2804036; women, part time, 2803480 oils, essential; history, formularies, 2805069
management, 2804508 pharmacy, community; chain stores, Rumex species; analysis, 2803367
pharmacy, community; antitrust laws compliance, communication, pharmacists and employers, Adverse Drug Reactions, 2803501
2804467; chain stores, job satisfaction, 2806474 see also 2800070, 2800118, 2800287, 2800289,
2802481; chains, relations, pharmacists, sociology; manager-employee conflict, resolution, 2800290, 2800291, 2800292, 2800293,
employers, 2805713; economic indicators, 2800252 2800294, 2800374, 2800446, 2800498,
2803409; employee motivation strategies, good women; pharmacy organizations, Great Britain, 2800879, 2800955, 2800968, 2800994,
customer service, 2805103; health foods, New 2803445 2800997, 2800999, 2801012, 2801013,
Zealand, 2805668; ownership, 2805659; Admixtures, see Additives; injections 2801028, 2801040, 2801327, 2801473,
ontsahwotimnerieldln riastpleha, ri tpgy2 r 8ot0rur2eap4in sm7ftb9eeu;rcr ,h snsei2umq8peu0ene0rt,2m, a7 r42k;82e 08t40sp52,r54 o17b;8El ;ne gmpl rausnrodall, v ingvi,t y, Adtnhreeerxvaiipteyiw;,s y dci2ian8g 0np1oh7so7iss4p, h attrea;n stmhiesrsaipoyn,, d2o8s0a1g3e,7 8 2802673 2222888800002314285248262702,,,, 2222888800001423558293967839,,,, 2222888800004124560960598510,,,, 2222888800002434026592176021,,,,
222888000526744030988;;; ttthhhiiirrrddd pppaaarrrtttyyy cppolrlaolnge,rc atcmioossn,t ab2ge8en0enf2ci9yt8 0ba ennaelfyistiss,, Adaoclnee;s cetnhetrsa py, 2804239 222888000445572723367,,, 222888000455502843259,,, 222888000455516847379,,, 222888000455617243180,,,
ph2a8r0m0a9c7y2 services; computers, databases, ccaadpletcloiipuvrmei;rl y; spaurlpobppulhmeyimlneaunxrtiissa,, tp2hr8eer0ga3np5ay8n,9c yd,i abperteetse rmme llitus, 22880065571339,, 22880056754105, 2806298, 2806498,
policies and procedures; adverse reactions 2806097 Adverse drug reactions, see Drugs, adverse
pPrhoatromcaoclesu,t i2c8a0l6 5E0d0u;c atAimoenr,i casnch olFaorusnhdiaptsi, on for dr2u8g0 4a4b9u7s;e ; buatnadn e,a lpcrohoopla naeb usien,h aleadtuicoant,i ont,o xicity, Adrveearcttiiosnisn g
a2g8e0n6t4s5,2 ;h osapnietsatlhse,t ic2s8,0 4426840;0 54a2n;t inaenotpilnaesotpilca staincd 2805214; trends, 1974-1988, 2805100 al2c8oh0o3l9s2,7 ethyl]; history, Plantation Bitters,
htarezaatrmdeonuts cdernutgers,, fhoanrdmluilnagr,y 2m8a0n0a2g2e7m;e ncta,n cer inssyulnidnr-olimkee, gdrioawbtehte sf amcetolrl itIu; se,f fe2c8t0s3, 54M7e ndenhall’s ccaopsmseitciucms;; hriesgtuolrayt,i o2ns8,0 50G6e8r many, 2805055
2804631; definition, clinical pharmacists role, psychotherapeutic agénts; behavioral and mental drugs; history, 2804482; regulations, EEC, 1992,
2800036; drug abuse testing, hospital disorders therapy, 2805873 2805634
Cphaanramdaac,i st2s8,0 4629890;3 92d0r;u g dralulge ragyb usdeo cuthmeernatpayt,i on, Ad2o8n0i3s8 83a murensis; cardiac glycosides; LC, em1p9l7o8y-m1e9n8t8,; p2h8a0r1m5a4c9i sts, U.S., newspapers,
hospital pharmacy, 2804621; drug information, Adrenaline, see Epinephrine geriatrics; improved pharmaceutical care,
Burroughs Wellcome, 2801562; drug Adrenaline bitartrate, see Epinephrine 804549
information centers, consumer inquiries, bitartrate hair dyes; community pharmacy merchandising,
2801909; drug information, communication, Adrenergic ard see Sympathomimetic agents 2806394
Upjohn, 2801564; drug information, Eli Lilly, Adrenergic blockin: g agents, see Sympatholytic ibuprofen; OTC status controversy, Canada,
2801563; drug information, Genentech, agents 2802443
2800279; drug information, Pfizer, 2800280; Adrenocortical steroids, see Steroids, cortico- industry, pharmaceutical; effects, ASHP events
drug information, pharmaceutical industry, Adrenocorticotropic hormone, see Corticotropin and publications, 2800016
2800281; FDA changes, 2801484; flammable Adrenolytic agents, see Sympatholytic agents perfumes; concepts, 2805663; creativity, 2804512
propellants, safety, pharmaceutical industry, Adriamycin pharmacists, community; guidelines, 2804503;
2804612; health care assessment, guidelines, see Doxorubicin laws, cases, 2
2801502; hospital formularies, 2801085; hospital see Doxorubicin hydrochloride pharmacy, community, 2804492; cholesterol
pharmacy, disaster planning, 2803493; hospital Adriamycin hydrochloride, see Doxorubicin scree:.ings, 2803439; health foods, New
pharmacy, discharge prescriptions, pediatrics, hydrochloride Zealand, 2805668; marketing, 2806409; patient
2801069; hospital pharmacy, pharmacist Adriamycin RDF, see Doxorubicin consultation, needs, Canada, 2803016;
monitoring and intervention, 2802527; hospitals, hydrochloride promotional packages, 2800257
computerized manual, 2800990; hospitals, HIV Adsorbents prescription drugs; direct to consumer techniques,
positive pharmacists, 2800241; hospitals, charcoal activated; and magnesium, therapy, 2802984; FDA regulations, 2804466; marketing
pharmacists documentation, medical records, theophylline overdose, 2803507; interactions, regulations, FDA, 2805640
2801062; hospitals, zidovudine prophylaxis, aspirin, review, 2801285; interactions, pricing; prescription drugs, pharmacists, cases,
HIV, personnel, 2805273; immunization, furosemide, diuresis, 2804159; local anesthetic 2803398
medical schools, Canada, U.S., 2803597; adsorption, 2804784; multiple doses, effects, regulations; drugs, EEC, 2806339; Rx and OTC
informed consent, antipsychotic drugs, 2800236; aspirin excretion, 2801630; poisoning therapy, drugs, Great Britain, 2803394
intravenous potassium use, 2800024; mail order 2801363, 2802688; poisoning therapy, Royal Pharmaceutical Society of Great Britain;
pharmacy, 2805125; pediculosis therapy, Great pediatrics, 2802464; therapy, paraquat ethics, 2805098
Britain, 2805660; pharmaceutical education, poisoning, review, 2803537 topical preparations; raw materials, selection,
Great Britain, 2805112; pharmacy management, Fuller’s earth; therapy, paraquat poisoning, 2802511
2800332; pharmacy recycling programs, review, 2803537 triazolam; generic equivalency, methodology,
2803961; selection, INN and Italian poly(y-methyl L-glutamate); endotoxins, 2804167
Nonproprietary Names, 2803453; therapeutic chromatography, 2803804 Aerosil, see Silicon dioxide colloidal
substitution, ACP, 2801079 polystyrene divinylbenzene; effects, Sterinol Aerosols
postmarketing surveillance; worldwide fax turbidity, 2803718 abuse; inhalation, toxicity, UK, 2801121
system, 2806513 Wofatit CA-20; effects, Sterinol turbidity, albuterol; toxicity, myocardial infarction,
research; policy issues, 2806437 2803718 2802565
specialties; hospital pharmacists, interest groups, Adsorption albuterol, comparison, fenoterol, terbutaline;
2804628 anesthetics, local; activated charcoal, 2804784 toxicity, inhalation, asthma therapy, 2805205
strategic planning; educational programs, cost chlorpheniramine maleate; film release, 2804194 chlorofluorocarbons; ozone depletion, alternative
benefit analysis, 2801532; VA pharmacy daunorubicin; polypropylene containers, 2806051 propellants, 2800228
services, conference, 2801958 doxorubicin; polypropylene containers, 2806051 cosmetics; non-gas, 2804586; regulations,
technicians; role, Michigan, 2801931 endotoxins; depth filters, solutions, 2804588; Germany, 2805055
tests, laboratory; cholesterol screenings, 2803197 limulus tests, injections, interferences, 2801582 cromolyn sodium; lung deposition, inhaler
University of Nebraska; College of Pharmacy, epirubicin; polypropylene containers, 2806051 devices, 2806238
history, 2804480 insulin; containers, administration sets, 2806050; devices; products, 2801952
women; strategies, 2805087 infusions, glass, rubber, 2805419 dosage; pediatrics, standardizaton, 2800620
International Pharmaceutical Abstracts
Aerosols Subject Index
dosage forms; review, 2805979 2804881; effects, ifosfamide pharmacokinetics, dapsone; toxicity, 2805223
drug administration; nebulizers, dilution, air 2802313; effects, mexiletine pharmacokinetics, mianserin; toxicity, 2804648; toxicity, New
entrainment, body size, 2803140 efficacy, 2806100; effects, pharmacokinetics, Zealand, 2805822
fenoterol, comparison, albuterol, terbutaline; anti-infective agents, review, 2804416; effects, Agrimonia eupatoria; constituents; roots, sprouts,
toxicity, | inhalation, asthma therapy, 2805205 pharmacokinetics, gastrointestinal drugs, review, 2805013
ide; regular vs intermittent, 2804993; enantiomers, pharmacokinetics, AIDS dementia complex; zidovudine;
asthma therapy, 2805250 2806198; estrogen therapy, geriatrics, 2805895; intraventricular therapy, lack, 2805912
fluorescein sodium; particle size, inertial fentanyl, sufentanil, percutaneous absorption, AIDS-related complex
impaction, 2804000 2806246; fleroxacin, interactions, theophylline, acyclovir and zidovudine; therapy, synergism,
hair sprays; history, present, future, 2804857; 2802746; high dose methylprednisolone, lack, 2801166
propellants, polymers, 2804795 thrombocytopenic purpura therapy, 2805269; CD-4; therapy, dosage, 2802044, 2802045
industry; technology, 2804004 hyperlipidemia therapy, survey, 2804695; didanosine; pancreatitis, risk, NIAID guidelines,
kaolin; particle size, inertial impaction, 2804000 indocyanine green metabolism, 2805559; 2801987; therapy, previous zidovudine therapy,
leuprolide; availability, dogs, 2804759 labetalol pharmacokinetics, 2802916; 2802028
leuprolide acetate; availability, 2804176 metronidazole resistance, H. pylori, 2806271; dideoxycytidine and zidovudine; combined
nedocromil sodium; radiolabeling, 2803709 mianserin toxicity, agranulocytosis, 2805822; therapy, 2805856, 2805857, 2805859
particle size; analysis, 2804943 oral contraceptives, relation, ovarian neoplasms, doxycycline; cat-scratch disease therapy, 2802092
pentamidine; P. carinii pneumonia prophylaxis, 2804310; pharmacokinetics, corticosteroid fluconazole, comparison, ketoconazole;
AreIvDiSe,w , 2288010743866;7 P. carinii pneumonia therapy, tphhearrampayc okmionneittiocrsin,g , 2820820951670;6 ; pnpeiurmazoocloaccc al kectaoncdoindaiazsoilse , thceormappya,r is2o8n0,3 11f4lu conazole;
pet.tamidine isethionate; P. carinii pneumonia vaccines, efficacy, 2803578; prescriptions, candidiasis therapy, 2803114
pprnoepuhmyolanxiias , th2e8r0ap1y1,7 1,2 80258403193;6 8;e nvPi.r ocnamreinnitia l spohcairaml acionksiunreatnciec,s , Hu2n8g0a1r4y3,7 ; 28re0l4a5t1io9n;, propofol zi2d8o0v5u0d1i7ne;; aanndd anAtIiDviSr alts,h erlaopnyg, tseurrmv ivtahle rampayr,k ernso,n -
toxicity, health professions, 2806331; lung propranolol-induced depression, 2805216; Hodgkin lymphoma risk, 2801713;
mdaiesslttlhrimitabu,us t,i oAnAI,ID DSSp,o, s t2u28r80e05 73e95f92f;2ec tst,o xi2c8it0y5,5 5d6i;a bettoexsi city, r22e88l00a23t7i0o38n37,;, tse2un8no0sx3ci0rc9ea1em;n traohgxeeinuctmista,yt ,o icldoa mcpkal,ri tah2rn8ict0ei3s, 0 8t1h,e rapy, dproehsvaiaregmwea,,c ok2Hi8In0Ve1 t3ii4cn6sf ,e ctimoondse,l s,2 80218106164;5 5;t herreapdyu,c ed
pproowpdeelrlsa;nt sp;a rtcihclloer inseiz e frdeeep, osmiettieorne,d 2d8o0s3e4 7i6n halers, 22880025182479;; ttehiecoopphlyalnliinn e,p haprumlamcoonkairnye tifcusn,c tiroenv,i ew, zitdhoevruadpiy,n e 28a0n5d 85d6i,d eo2x8y0cy5t8i5d7i,n e;2 80c5o8m5b9i ned
2803456; flammable, safety, 2804599, 2804612 2801777; therapy effects, 2806138; uricosuric
regulations; environmental toxicity, 2805054 agents, utilization, Spain, 2802694 Ai2z8o0o3n2 25c anariense; effects; cytotoxic, in vitro,
respiratory tract diseases; inhalation therapy, pediatrics; American Indians, Haemophilus b AJ-2615; chromatography, liquid; plasma, dogs,
pharmacokinetics, 2802315 polysaccharide vaccines, 2803582; amikacin rats, 2805530
rie2bna8vv0ii4rr1ion1n;9 m,e andt2mai8ln0 i4s4tt6or1xa;itc iiotanye ,r osshyoeslatsle,t mhs 2,p8 r0op4fe4ed1is5as;tir oincss,, pcdhhoalproamrmapicrnooekm ianzpeihtnaierc msa,pc hoakdriomnsaeactgoiekc,is n,e2 t8i02c18s40,21 04;02 88;0 18ef7f1e;c ts, Alparobgarmaam s,S oc2i8e0t0y3 3o3f Hospital Pharmacists;
2802391, 2804462; environmental toxicity, deferoxamine, thalassemia therapy, 2801176; 280479€;4 permeation; small unilamellar vesicles,
recommendations, 2805621; paramyxovirus ergocalciferol, 25-hydroxyvitamin D, 1,25-
infections therapy, pediatrics, 2806405; dihydroxyvitamin D levels, 2801372; Alantolactone; allergies; contact dermatitis,
respiratory syncytial viruses therapy, pediatrics, Haemophilus b conjugate vaccines, antibody cysteine therapy, guinea pigs, 2802859
2802082, 2802091; respiratory tract infection levels, formula vs human milk, 2803614; Alaska; Haemophilus b polysaccharide conjugate
therapy, 2804106 Haemophilus b oligosaccharide conjugate vaccines; immunization, pediatrics, Alaskan
salmeterol; allergen-induced asthma, prophylaxis, vaccines, immunization, 2802634; Haemophilus natives, 2803583
2804078 b polysaccharide conjugate vaccines, 2803586; Albendazole; larva migrans; therapy, 2802145
suspensions; controlled flocculation, 2801054 measles immunization, antibody levels, Albumin
sympathomimetic agents; toxicity, asthma, 2804700; methylprednisolone, asthma therapy, absorption; intestinal, bile salt effects, rats,
deaths, 280580. infants and toddlers, 2801187; mineral 2801296
terbutaline, comparison, albuterol, fenoterol; supplementation, effects, magnesium binding; phenylbutazone, warfarin, analysis,
toxicity, inhalation, asthma therapy, 2805205 metabolism, preterm infants, 2801414; patient 2806208
toxicity, environmental; clean air regulations, criteria selection, erythropoietin, premature complexes; penicillamine disulfide,
California, 2805059 infants, 2801230; preterm infants, globulin pharmacokinetics, 2805347
Aethusa cynapium; toxicity, 2805832 immune, effects, natural killer cell activity, crosslinking; hydrogels, swelling, degradation,
AF-150; chromatography, liquid; and metabolite, 2803188; sulfamethoxazole-trimethoprim, 2805995
blood levels, rats, 2804962 pneumonia therapy, India, 2802104; younger vs effects; interleukin 1B stability, infusion systems,
Affective disorders older, typhoid vaccines, capsules vs 2804809
anticonvulsants; therapy, 2805928 suspensions, 2802057 liposomes; charge effects, 2804172
therapy; refractory, 2800809 pharmacists; attitudes, pharmacy practice, lyophilization; moisture, vials, 2805760
Affective symptoms; valproic acid; therapy, education, 2805145 microspheres; cyclophosphamide targeting, liver,
mentally retarded pediatrics, 2801196 women; androgen excretion, breast diseases, mice, 2804181; doxorubicin, intratumoral, rats,
Aflatoxin B ,; contamination; crude drugs, 2801827; estrogens, hip fracture prophylaxis, 2805499; size distribution, drug release,
2803872 2801626; menopause, calcium effects, 2803470; streptomycin, properties, 2804178
Africa; imports; drugs, from India, 2806422 osteoporosis prophylaxis, 2803101; transdermal, utilization; hospitals, shortages, 2804034; review,
Afzelin; Cercis chinensis; flowers, 2805009 vs oral hormone therapy, menopause, 2803616 2800602
linemia Agglomeration; maltodextrin; methods, Albumin bovine; effects; drug dissolution,
globulin immune; therapy, adverse reactions, micromeritics, 2804614 crystallization, 2806027
anaphylaxis, 2804636 tion Albumin human; and heparin; microspheres,
RF-HBs-1; monoclonal antibodies, hepaiitis B barbiturates; powders, aqueous suspensions, doxorubicin release, 2801683
virus infection therapy, 2802038 particle size, 2801695 Albuminuria
poloxamer 407; diacryloyl derivatives, 2804202 captopril; therapy, diabetes mellitus, adolescents,
effects; epilepsy recurrence, risk factors, poloxamer 407 derivatives; hydrogel formation, 2800097
2803173; skinh 2803892 2804203 nifedipine, comparison, perindopril; therapy,
geriatrics; xamoterol blood levels, cardiac effects, Aggression — diabetes mellitus, 2805838
2800204 carbamazepine; therapy, 2805928 perindopril, comparison, nifedipine; therapy,
outpatients; drug utilization, Czechoslovakia, vigabatrin; toxicity, aggressive behavior, 2802004 diabetes mellitus, 2805838
2805 104 Aging : triflusal; renal hemodynamics, diabetes, 2805251
patients; ACE inhibitors, therapy, systemic effects; cardiovascular systems, 2804894; drug Albuterol
scleroderma, renal crisis, 2801190; adults, metabolism, review, 2806265 alone and with methylprednisolone sodium
pneumococcal septicemia, rare, 2802922; geriatrics; skin problems, therapy, 2804276 succinate; asthma therapy, infants and toddlers,
aerosols, drug dilution, air entrainment, immunology; responses, review, 2804352 2801187
2803140; alfentanil pharmacokinetics, 2806267; oxygen; radicals, toxicity, 2801604 and MK-571; effects, smooth muscle tone,
aminoglycosides, toxicity, kidney, 2805815; patients; percutaneous drug absorption, 2805002 asthma therapy, 2802611
amlodipine effects, blood levels, 2804976; selenium, therapy, 2805479 asthma; therapy, 2806091
amoxicillin-clavulanic acid pharmacokinetics, skin; tretinoin effects, sun exposure, 2806098 bronchiolitis; therapy, pulmonary function,
2802824; analgesics, nonsteroidal anti- tablets; effects, strength, 2805987 1
inflammatory agents, GI hemorrhage, 2804642; Aglaia roxburghiana; extracts; anti-inflammatory comparison, fenoterol, terbutaline; toxicity,
antibiotics, asymptomatic bacteriuria therapy, activity, 2801388 inhalation, asthma therapy, 2805205
2800100; atriopeptin, effects, 2801718; Aglycones; Artemisia annua; flavonoids, concomitant therapy, 2802147
captopril, sublingual, ACE inhibitor test, constituents, 2806279 consultation; metered dose inhalers, pharmacists
2805880; cefmetazole pharmacokinetics, dosage, effectiveness, lack, 2803964
2804965; clomipramine metabolism, models, clozapine; toxicity, distribution problems, depression; therapy, 2803238
2805036; cyclosporine-diclofenac interactions, 2805086; toxicity, mandatory monitoring, dosage forms; pharmacokinetics, controlled
toxicity, kidney, 2805945; effects, dry skin, dispensing control, 2801497 release vs regular tablets, 2801288
1220 International Pharmaceutical Abstracts
Subject Index Allergies
effects; cation transport, 2804281; toxicity, ape es blood levels, cardiac effects, Commelina benghalensis; isolation, identification,
platelet activating factor, mice, 2802856 5; nonsteroidal anti-inflammatory agents, 2804435
inhalers; metered dose, comparisons, 2804189 3804750: patient consultation guidelines, Cordyceps species; C. sinensis, C. hawkesii, .
patches transdermal; osmotic delivery, 2803711 pharmacists, 2803011 comparison, 2803368
therapy; nebulizer, urticaria, zidovudine adverse pregnancy; relation, cocaine abuse, 2803410 Delphinium kamaonense; roots, 2805594
reactions, 2802556 propellants; metered dose inhalers, 2803456 Eschscholtzia californica; cell cultures, isolation,
toxicity; myocardial infarction, nebulized therapy, safety; risk management, hospitals, 2802548 2801884
2802565 teratogenicity; toxicity, infants, 2801129 harmalol; fluorometry, 2803795
Albuterol sulfate toxicity, 2802439; intestinal mucosal injury, harmol; fluorometry, 2803795
— idiopathic, combined therapy, 2802592; models, methodology, 2805032; sex Holarrhena antidysenterica; turbidimetry, 2803336
2801632 disorders, 2804652 Ipomoea species; lysergic acid derivatives,
comparison, terbutaline sulfate; breath-actuated vs vehicles; effects, 2-chloro-2' ,3'-dideoxyadenosine isolation, 2805006
pressurized inhalers, 2804735 stability, 2802784; minoxidil, topical absorption, Lobelia species; content, cultivation origins,
concomitant therapy, 2802588 2801861; neomycin suspensions, reduced 2800216
interactions; pancuronium, neuromuscular antibacterial effects, 2803356; sulfiram, adverse Lycianthes biflora; steroids, isolation,
blockade, 2802750 reactions, 2805798 identification, 2806280
matrices; polymers, tablets, 2803708 withdrawal; anticonvulsants, therapy, 2805928; Phyllanthus discoides; leaves, isolation,
microcapsules; release kinetics, 2804218 therapy, clonidine, 2802247; therapy, Ireland, antibacterial effects, 2802368
release; microcapsules, methodology, 2801697 2802447 plants; medicinal, interactions, anesthetics,
sustained-action; floating capsule, 2805385 women; toxicity, 2802585 2801612
AlacnUod.h So.dl riussgum r avbeuys,e ;2 8c0o3m9o3r5bi dity, mental disorders, anpdo laycmeet9or n ef;i lmpso,l yy2ml8e 0r3 1—6 2803166; solvents, RSooielsomalenarutiimoa n ,s hpye2bc8ir0ei1sd;8a ;8 6st perrooaidpso,r phisionlea-ttiorny,p tamines,
eeddpuurccoaagttroiraosmn;;s , pmhe2ad8ir0cm5aa1lc0 y6,;s t uadptehtnaittrsum,d aecs2,y8 ,0 t0r2seu6ar6tvm eeyn,t 2805105 Alacnaodbh sooelrsp,t riomne,t hy2l—8;0 4s e nialed, eal cophohlyss,o stetihgymli;n e AlTkaaibdleeonsrtinisaf;ie cmatothineotrnaa,n pya2; 80cmr6ea2tsa8sba0;o liics,o larteisopn,i ra2to8r0y3,3 8228 06150
folk medicine; therapy, Hungary, 2804516 tissue ype plasminogen activator release, Alka-Seltzer, see Aspirin; combination, citric
geriatrics; relation, prescription drug abuse, 2805459 acid, sodium bicarbonate
2804505 Alcohols, octyl 3-Alkoxy-3,4-dihydro-1H-2-benzopyrans;
he2p8at0i0t1is2 5 B vaccines; response, Alaska Natives, and water; beta blockers, partitioning2g , Alsyknotxhyespihse, ny2l8c0a3r76b5a mic acids; piperidine ethy!
pharmacists; employment, recovery, ptahreernmtoerdayln acmoinctsa,i ner2s8,0 6020830;1 33—7 ——- solutes, esters; structure- -activity, G| c. 2806186
considerations, 2805071; Minnesota, attitudes, comparison, water; solvents, anesthetics, molal N-Alkyl 2-carboxy-8. esters;
programs, 2806410; rehabilitation programs, volume, 2805373 synthesis; xanthine oxidase inhibition, 2803761
2802425 solvents; chlorpromazine partitioning, ion pairing, 6-Alkyl 2-methoxy-1,4-benzoquinones; synthesis;
physicians; precursors, 2801915 2806002 primin derivatives, 2802862
rsittuadnesnetrsi;n ; phtaherrmaapcyy,, 28at0t5i2tu4d4e s, programs, 2801516 Al2c8o0h5o7l5s1, phenylethyl; use; perfumes, flavors, synthesis; local anesthetic)- ‘1 e,f2f-ebcetns,z i2so8t0h3i7a6z0o les;
therapy, 2 2 Alkylating its, see Antineoplastic agents
toxicity; cardiomyopathy, 2801128 Alcohols, propyl; comparison, alcohols, ethyl; 3-Alkyl-N-hydrox: ide derivatives;
tissue type plasminogen activator release, synthesis; inhibition, human jeukocyte elastase,
ccoo2nm8cb0ei4nnt7ar7ta3it oino,n ; liRd.o coafifniec;i naelmiusl seixotnra ctgse,l s,2 8r0e5le5a9s2e, AAll2cd8oo0ls5ee4c 59r6e 6d2u,c tsaesee Leicnihitbhiitno rs 1-2sOy8n-0tA5hl5ek0syi3sl ;- 2a-nOt-imteutmhoyr l-erfafecc-tgs,l ycine rvoiptrhoo,s p2h8o0l1i3p9i9d s;
ef2fe8c0t1s3; 06s;t rattiusms uec otrynpeeu mp latshmeirnmoogternop iacc tibveahtaovri or, ddii2aa8bbe0ett5ie4cs9 1n meepllhirtoupsa;t hcioemsp;l itchaetriaopnys,, 2t8h0e4r8a1py7, review, 5-aAnltiklyilp-e5m-ipc,h enryatlsb,a rmbiicteu,r i2c8 04ac8i4d4s ; effects;
release, 2805459 Allantoin; effects; mutagenicity, hydroquinone
esters; synthesis, 2804936 diabetic neuropathies; geriatrics, therapy, creams, 2803536
Overhiigclaensu;m insdiopmyleetuhma;c ino ilsg,e lse,s seanbtsioarlp,t i2o8n,0 2924810 1674 22880042267196; therapy, 2804818; therapy, review, AlElnegnl aandn,d H28a0n3b9u2r4y s; history; Quaker influence,
2803539, benzyl; excipients; toxicity, side effects, kpohlaarvmiarcono;l ogeyff,e ct2s,8 01ra3t5s,0 2801392 Alclyesrtgeeinnes ; thaelraanptyo,l ac2t8o0ne2;8 59c ontact dermatitis,
Altciosshuoel st,y peb utpylla;s mcionmopgaerni soanc,ti vaatlocro horlesl,e aseet,h yl; AAllffaa -2ian-tienrtfeerrfone,r ons,e e saee- Inat e2r,f-Ienrtoenr feron alantolactone; contact dermatitis, cysteine
2805459 Alfaxalone; effects; muscimol binding, ‘y- therapy, 2802859
AAllrcceoolehhaooslless,,, 2ce8et0thy5yl3l; 9 5e ffects; polymer coatings, lithium Alapfemedinintaotabrnuiictlsy ;r iscc olaicoisdi s refcuespitoonr s,s ur2g8e0r2y,8 182 800684 aalnatidesvptelraresspele,a srece,oa mcctpioaomrnpisas,ro in2s,8o 0na1,n 6i4sa8tlr teeppllaassee,, ssttrreeppttookkiinnaassee,;
absorption; skin, sodium salicylate, effects, pharmacokinetics; patient age, sex, 2806267 adverse reactions, 2801648
ab2s8o0r1p6ti7o n enhancers; iontophoresis, polypeptides, Alugtiilniaztaet,i on;s eer eAvligeiwn,i cc osatc ids avings, 2800675 aannttiibhiiosttiacms;i nepsr;o toOcToCls,, phaotmieen t thceornaspulyt,a t2io8n0,0 955
2804757 Aiginic acid; stability; impressions, disinfection, pharmacists role, 2805721
abuse; attitudes, pharmacy students, survey, 2804229 aspirin; desensitization protocols, 2802242
2801516; cardiomyopathy, 2801128; Algorithms, see Protocols; algorithms aztreonam; adverse reactions, anaphylaxis,
comorbidity, mental disorders, U.S. survey, Alkalies; poisoning; symptoms, treatment, 2801975
2803935; geriatrics, 2804505; laboratory tests, 2803066 barium sulfate; adverse reactions, enemas,
health professions, 2801511; medical students, Alkaline protease; biosynthesis; bacterial, 2801981
survey, 2802450; pediatrics, adolescents, stability, 2803870 bites and stings; insects, immunotherapy,
2804497; pharmacists, intervention, Alkalinizing agents pediatrics, 2805289
2804493; pharmacists, programs, interventions, combined therapy; eosinophilia, tryptophan candidiasis; hypersensitivity syndrome, nystatin
2805088; pharmacy educators attitudes, Press < 2804719 therapy, 2605287
2805106; pharmacy educators, survey, 2805105; sodium bicarbonate; alkalinization of bath water, cefaclor; delayed hypersensitivity, serum
pharmacy students, Puerto Rico, survey, aquagenic pruritus, 2805904; combined therapy, sickness, 2801096
2802430; pharmacy students, survey, 2805673; kidney failure, multiple myeloma, 2802139; cephalosporins; third generation, 2801607
physicians, precursors, 2801915; pilots, drinking hyperkalemia, combined therapy, lisinopril ciprofloxacin; adverse reactions, serum sickness-
and flying, U.S., 2801501 toxicity, 2803513; incompatibilities, milrinone, like syndrome, 2801983
advertising; history, Plantation Bitters, 2803927 injections, 2802188; interactions, encainide, cosmetics; contact dermatitis, 2802557; incidence,
and water; sulfacetamide photodecomposition, flecainide, 2804745; toxicity, proteinuria, 2805201; skin effects, assessment, prevention,
2805425 infants, 2800044 804051
athletes; toxicity, 2804049 sodium citrate; and arginine, argininosuccinate cross; cephalosporins, 2803196
beverages; thiamine additives, Australia, 2801514 lyase deficiency, pediatrics, 2801216; decomposition products; hypersensitivity ,
diabetes mellitus; complications, 2804862 crystalluria, AIDS, 2805218 analysis, 2805239
effects; beta-endorphin, hydrocortisone, blood tumor lysis syndrome; therapy, 2805827 dermatitis; contact, therapy, 2804872
levels, 2806099; gelation, poloxamer 407 Alkaloids desensitization; anaphylaxis prophylaxis, 2802218
diacryloyl derivatives, 2804202; tissue type Aconitum tschangbaischanese; diterpenes, roots, dextromethorphan; fixed drug eruption, 2805199
plasminogen activator release, 2805459; 2803879 diagnosis, 2803504
triamcinolone absorption, patches transdermal, Artabotrys maingayi; isolation, 2802362 drugs; adverse reactions, Sjogren’s syndrome
2801680 Buxus papillosa; steroidal, isolation, 2802363 patients, 2805790; contact dermatitis, therapy,
hemorrhage; injections, therapy, hepatoma, Castanospermum australe; seeds, isolation, LC/ 2801352; documentation, hospital policies,
2801183 MS, 2802364 2804621; immune reactions, mechanisms,
interactions; aspirin, blood levels, 2804155; Colchicum ritchii; colchicinoid, catabolism, 2800075; OTC therapy, rash, 2805231; patient
clomipramine, metabolism, models, 2805036; isolation, 2802934 histories, evaluations, 2800374; protein-
International Pharmaceutical Abstracts
Allergies Subject Index
photoallergen conjugate photosensitivity, Alteplase AM-833, see Fleroxacin
mechanisms, 2801985; skin reactions, 2800043; adverse reactions; purpura, 2801982 Amantadine
structure-activity relationships, models, alone and with heparin; thrombophlebitis therapy, effects; dopaminergic neurons, rats, 2804303
2802269; transdermal delivery systems, 2803658 2801251 — malignant syndrome; therapy,
erythromycin ethylsuccinate, combination, and aspirin or heparin; myocardial infarction 01728
sulfisoxazole acetyl; epidermal necrolysis, therapy, 2805887 Parkinson disease; therapy, 2803204
pediatrics, 2802552 comparison, anistreplase, streptokinase; therapy; cocaine withdrawal, 2804724
extracts; compounding services, 2800389 myocardial infarction therapy, 2801648 toxicity; edema, geriatrics, 2803544
food; lactose intolerance, 2804839; lactose concomitant therapy, 2803525 Amantadine hydrochloride; therapy, 2804874
intolerance, patient education, 2804826; cost benefit analysis; Canada, 2805657 Amastatin hydrochloride; effects; somatropin
hissytmampitn1oe6m;8s ,s kitnh ersaepnsyi,t iv2i8t0y,4 04p3r ovocation times, dcoi2sltu8st0;i0 o9nAs1c;4t igvuaisdee liFniensa,n ci2a8l0 0A7s3s2i stance Program, Ambnaobsdaaylz odanibesst orripbtuitoino,n; etnuhmaonrc emfreenet ,v s 2t8u0m2o7r5 4b earing
ppklaeolc2ntlae8ooynrlt0steii3aoanflr0g;esbo 5n,a ;7 t t ose2xet i8ehcd0e8i;r30t a;y5p ,a0y de2,vx 2 ce8irr0psei3eve 6in8etr4wse, ,a ct2Ti8oPn0Ns5,,8 4a8vni atpamhiynlsa,x is, eeimfnmyp2fdboee8icodc0citala4asrit3;tdis r1oimi2noa;c;scls ;,c lptiuuih2ndnlef8etrma0edaorn4 pcns1ytaici,3rveo 2enyn t;,rr e acvlatapr hseeec dvriueaualnpntaoyirrut,iiss cz, sa 2,t c82ia0o82t3n0h82 e106t81r8e0a2r,t82s e, 5s , meta- dceoaomcmcxiopticimadevrpa,itio tissy2o,oin 8nt 0,ir5 ook5dnide7n nei5tthp isryc,ods d,ru 2oc8at20ms81;b0 3a09z1d5o6i n7he y;d roaantmibnaezooplnaes tic
pprreospehryvlaatxiivse;s ; hocomnet acgtu idleelnis nesso,l ut2i8on0s2,2 232 803969 pualnamloynsairs,y 2e8m0b0o0l9i1s;m ; thtehrearpayp,y , repvrieegwn, an2c8y,0 1709 ef2fe8c0t5s;4 87i mmunological, human lymphocytes,
quinine; adverse reactions, kidney failure, 2803595 Ambazone derivatives; effects; immunological,
2800038 recombinant; genetic engineering, 2801954 human lymphocytes, 2805487
quinine sulfate; liver, hypersensitivity, 2801095 thrombosis; aortic, neonates, 2801235 Ambroxol
rifampin; fixed drug eruption, 28 Althaea officinalis; extracts; anti-inflammatory alone and with clenbuterol hydrochloride;
salmeterol; asthma, prophylaxis, 2804078 activity, 2801388 availability, tablets, 2802170
streptokinase; adverse reactions, low back pain, Altitude sickness chromatography, gas; biological samples,
2804635 acetazolamide; therapy, taste disorders toxicity, 2803793
streptokinase, comparison, alteplase, anistreplase; 2802566 Ambroxol hydrochloride; chromatography, liquid;
adverse reactions, 2801648 carbon dioxide, comparison, oxygen; therapy, dosage forms, 2803329
sulfamethoxazole, combination, trimethoprim; 2805905 Ambulatory care
desensitization, pediatrics, HIV infections, oxygen, comparison, carbon dioxide; therapy, clinical pharmacists; role, obstetrics and
2805905 gynecology, 2800334; seizure clinic, 2801963
sulfites; content, prescription, OTC dmgs, Altretamine diagnostic agents; in vitro, marketing, 2800245
Australia, 2801327 injections; dosage schedules, pharmacokinetics, economics; marketing, nonhospital health care
sulfonamides; desensitization therapy, AIDS 2802048 systems, 2801911
patients, 2800118 neoplasms; therapy, review, 2804861 errors, medication; prescription correction forms,
tests; skin, methods, 2800639 D-Altrofuranoheptulose; Rhodiola henryi; 2800034
therapy, 2801361; home emergency kits, 2806058 rhizomes, 2806281 geriatrics; medication practices, 2800916
vaccines; patient histories, forms, 2806496 Alum ammonium; irrigating solutions; outpatients; pharmacokinetics monitoring,
vitamins; excipients, polysorbate 80, 2803057 compounding, 2804767 2800962
zidovudine; adverse reactions, urticaria, 2802556 Alum potassium; irrigating solutions; patient information; consultation, hospital
Altium sativum compounding, 2804767 pharmacy, 2801068
effects; androgenic, extracts, mice, 2802243 Aluminium, see Aluminum pharmacy services; computers, selection,
meningitis; therapy, 2802126 Aluminium hydroxycarbonate, see Aluminum 2801029; formularies, 2800377
Afftum ursinum; oils, essential; folk medicine, hydroxycarbonate quality assurance; outcome indicators, 2801957
Hungary, 2805599 Aluminum residencies; programs, 2800267
Alopurine! chromatography, gas; dosage forms, 2803338 substitution; therapeutic, ACP policies, 2801079
and dimethyl! sulfoxide; duodenal ulcers, rats, effects; mineral oil emulsions, 2803164 Amdinocillin; interactions; cefotiam,
2801806 nutrition; infant formulas, loading, kidney failure, Enterobacteriaceae, 2802742
chromatography, liquid; plasma, rats, 2803805 2801232 Amdinocillin pivoxil; alone and with
colchicine and indomethacin; gout therapy, toxicity, 2804876; anemia, lack, hemodialysis, pivampicillin; reactive arthritis therapy, enteric
pytazinamide adverse reactions, 2805795 erythropoietin therapy, 2802100 infections, lack, 2805280
psor2lou8db0riu3lg7ist0y;6; seyfnftehcetssi, s,g enatviasiilca bialciitdy , etrhababniotlsa, mi2d8e0,5 961 AAllniuutmmrioifnnuuurammn toccihhnl loorsriuodshepy;ed nrscaiootnnecs;e, n tdr2ea8ot0dio1orn6a;9n 6t esf;f echtysb, rid AAmmmeeibncirocoriordrhegesaa;n; i sCmGt ePs-mto2od9set1le;,r o nmee;el tucatibodoxalitciiisotmny,,, t2o8p0i2ca9l4 2
solubilization; effects, cosolvents, 2803161 powders, texture, effects, 2805381
iP 'y, nuclear ic resonance; dosage Aluminum hydroxide preparations, 2802574
forms, 2801852 combination, calcium carbonate; interactions, American Academy of Pediatrics
tumor lysis syndrome; therapy, 2805827 lornoxicam, pharmacokinetics, 2803652 protocols; dexamethasone therapy, bacterial
Alamfvioanipolexaribdiiiianll io;tly , kdeerrraaibtbviianttosic,vy ets2e;8s ,0 5s9yb6nit1nh deisnigs ; siptreos,d ruagbss,o rption copiimnrnbtocieosrnmtaapacatgttiliioaobnnnid,sli, i ntsmif,eal sgu,ncu openpnsaeiizrzuoa lmtGei Id,i, hn yepd2,hr 8ao0rx23mi81ad02ce27o;7;k 8 i0en;fef teicctss,, mto2hel8eni0rig2ano6pgs3yia,4tc i csh2,a8 r0i25d88e07 162c;1o n7jH;u ageadmitoaepr rhhviealacu,c si noerbsa, l rienhfayndtrsa,t ion
kinetics, 2804355; percutaneous absorption, 2804740; interactions, lornoxicam, American Association of Colleges of Pharmacy
radiation induced erythema effects, 2806234; pharmacokinetics, 2803652; interactions, administration; mission statement, pharmaceutical
therapy, toxicity, hemangioma, 2804047; norfloxacin, absorption, 2802163 education, 2801518
therapy, women, 2805897 combination, magnesium hydroxide, simethicone; data collection; pharmacy degrees, enrollment,
therapy, 2802678 interactions, SCH-39304, pharmacokinetics, U.S., 1989, 2802455
areata 2805952 American Association of Pharmaceutical
anthralin and minoxidil; therapy, 2805321 compliance; calcinosis, kidney failure, 2804712 Scientists
a 2-interferon; therapy, 2805322 surface area; granulations, particle size, 2801057 data collection; salary survey, 1990, 2805655
minoxidil and anthralin; therapy, 2805321 Aluminum hydroxycarbonate; mechanism of reports; education and recruitment, need, 2801928
, see Alfaxalone action; cytoprotective effects, 2802846 American College of Physicians; policies and
Alprazolam Aluminum magnesium hydroxycarbonates; procedures; therapeutic substitution, 2801079
and amoxapine; panic disorder therapy, 2805295 X-ray diffraction; purity, crystals, 2802278 American Council on Pharmaceutical Education
and triazolam; withdrawal, psychoses, 2802588 Aluminum salts; antiperspirants; antibacterial accreditation; clinical clerkships, curriculum
comparison, etizolam; anxiety disorder therapy, effects, in vitro, 2804291 standardization, need, 2801524; experiential
2804680 Alvedon, see Acetaminophen programs, evaluations, 2801525
concomitant therapy, 2800060 Alzheimer’s disease degrees; PharmD entry level, attitudes, 2804532
effects; toxicity, platelet activating factor, mice, central nervous system drugs; research status, guidelines; proposed, PharmD only degrees,
2802856 2800084 2800268
ergoloid mesylates; therapy, lack, 2801207 American Foundation for Pharmaceutical
diffusion; intestinal epithelium, 2802946 nicotine; therapy, 2805277 Education; scholarships; policies and procedures,
effects; sperm motilityg2801360 selegiline hydrochloride; depressive disorder and 2806452
prodrugs; oximes, Imic solutions, 2801672 dementia, therapy, 2801716 American Journal of Hospital Pharmacy
Adprostadil tacrine; therapy, 2805277 articles; staff pharmacists, relevance, 2801559
effects; activity, uses, 2804311 therapy, 2804290; research, 2804271; review, history; impact, 2800969
impotence; therapy, 2804891 2805460 journals; ASHP, distribution, 2802489; contents,
shock; therapy, 2804277 velnacrine maleate; toxicity, dosage, 2805225 changes, current trends, 2801938
Alrestatin; diabetic neuropathies; therapy, review, AM.-682; alone and with terbutaline sulfate; publications; ASHP, 2801561; role, pharmacists,
2802616 bronchodilation effects, guinea pigs, 2804166 practice, 2804569
1222 International Pharmaceutical Abstracts
FOS as Sk SE OT 7 Sa ae
Subject Index Aminohippuric acid
American Pharmaceutical Association Amino acids and nafcillin; comparison, ciprofloxacin,
drug utilization; review, national program, Aminosyn II, see Aminosyn II osteomyelitis therapy, 2801267
2803431 arginine; and sodium citrate, argininosuccinate and penicillin G; bacterial endocarditis therapy,
guidelines; drug selection and purchasing, lyase deficiency, pediatrics, 2801216; high dose
2802400 effects, hypotension, 2804254; trauma, bacterial and vancomycin; endocarditis therapy, 2802723
litigation; prescription pricing advertising, infections therapy, review, 2804848 blood levels; prediction, cystic fibrosis, 2800873;
2803398 D-arginine; high dose effects, hypotension, toxicity, predictions, 2801451
meetings; highlights, 1990, 2802449 dosage; intrathecal, preparation guidelines,
American Psychiatric Association; attitudes; branched chain; critical care therapy, 2804847; 2803490; methodology, calculators, 2800218;
clozapine closed distribution, 2805086 glycogen storage disease type II, 2804140; liver once daily therapy, 2800790
American Society of Consultant Pharmacists; diseases therapy, 2804702; parenteral nutrition, dosage schedules; applied pharmacokinetics,
reference books; drug utilization review, 2806499 liver transplantation, 2805931 2802910; computer simulation, 2802952
American Society of Hospital Pharmacists chromatography, liquid; derivatization, gentamicin; P. aeruginosa, corneal infections,
dastuar vceoyl,l ec1t9i9o0n,; h2o8s0p3i0t5al1 ; phhaorspmiatcayl pshearvrimcaecsy , f2l8u0n3o3x1a3p rofen, 2802284; separation, injections, e2n8d0o5c2a2r7di;t isa,n d 2p8e0n2i7c0il4l;i n aGn,d Cv.a ncxeormoysciis n,
U.S., 1990 survey, 2802522 combination, dextrose; interactions, ampicillin, peritonitis therapy, CAPD, 2805270; blood
guidelines; continuing education programs and pharmacokinetics, 2803647 levels, gravity flow vs infusion pumps,
hacatziavritdioeuss, 2d8r0ug0s2,6 3;2 80h0a2n2d7l;i ngp haanrtmianceiosptlsa stic and conmubtirintaitoino na,d midxetxutrroes,e , pefdaita termiucsl,s io2n8s0;4 133-3i;n -1 22880011845335;; bblloooodd lleevveellss,, pirnetdeircfterieonnc,e , nopmeodigartarmicss,,
documentation, patient medical records, peripheral TPN, 2805939 2800223; hydronephrosis, therapy, pediatrics,
jOphnmpoereremaae2Pm2A2uaowoenddu8orh88Jlsfttvudnint0a00loeHiecaihi1becsr41Pnrla etto0sum55gt,stnotli6sasci38; icesro2as;c 77oer;inri; yCn ,s enaAn ,BP,; ;lgegJa ,u ,f,pHnt df hhtAaiPcecgiomdcacoo,S2e2eitmmnhrm 8t8Hssliteimp ,0t0iceP,e aeCrn3r0n vRiPtecot90pbees,eb,y11uhSscNm in 0t6p,aoeeacie crnwl2nteococms e8tn;in2ilac, 0 atle8cph 2leitren0rpn 4atiou22eth8tecpt8Pc4sai8rihrio0,8ro,a yagc 2m6n nclna4a staicl8c,cixth 9io Aciians;ecosnit2t tn,gnes 8, denG,C0 uotsrl 24s,f,iop8t6 n curr02iop1oytc229n9,ga a68t 9r rl08i0g aen;17nmt u9e s i3e,nd8 g,; Ccgppsttinetyaeulneoccdtafisaustpcurretehobnnorrttotmsdrifectirmieim,aelmryttonimipd pimaaieamacunteaattiot;ppzlelresytrnin iyaia;;a;iipi;tet,o b d sbc rsis;i noi,ihesp otbd r;ml po,vrhrinae eiam ismoelet,a,tr2oepirvdoes im e28newtairrmencic0a8,ipyeaust22hdil 5e0y;wl;eg88eaa s9, ,2l r s00t,2 n3 a8; ia30i8ael2i5 canous3720,n;s9ttltinn tC6638 imer eaii .1850vror cnln i,0t 4nfyaetp t h68ecosomoyae;lri4fdp,emltrie n e2lleaahcnexala tcp,cnwistscart yesnaurttro,i,o yiapi 2s nnvosncp,8iein, ,vl rd0td-, e erer3a isaComuv7znig2,.2gie2co4de 8se8nl8ln5u0,wt0eh2t0ec; ,0sa6as80,e ,1t,w1 70dc i6kh67 p12oea4a922482rsnr ; 83t80i,e ,0905in 4 0,t4e7 75ir92n5af14 la; ,n t ggeeet2rspp2rhta22Annfoaoeumlhe8888Ifttxbxsrpaam0000Deibiaaivisra1055cciScsmmecmmtt2i2ti39t,iiysiatstao21a58 ,cc,y,ylpcnl6022 ii ,,lhcoo;;;;t nneiekg 22 h2 ,nriihk88e8 -enreciirrr00as0sseeeneaad uen301uisltsrtplnnd602lieeisfiyine t477asrsab,,nceyes60ttat9ap gs oreeaca;;;ic ,op,;ntnp 2 t2f c lcicelaa88oeoearoopikamb00,n,cTasslphni,os 10sccumPhadd, ,nira28stN r neESlel25,,hm.c.le cg49 c oi aayel; shnccl vtrcii2t ;a2esoimoynsn 8rl 8lmapkif,dpcei0th0ee iccdv,ahori5cn2ane eiama,t2t23tlxecl yrip8s-sd32tst ocme,s,r0,r852in iadc o 1o; a8csirncps5c, d0saa2,osevt 1et1,t 8k,i ix2r 4c is0v2it;h4dccan2c8r e t5iotoes0a0fols;e,mt1dfnx2buid peii0i te8l,cscac;yno 3teissr,t o4stau s,id,;ysl, s ,fe o a,tn e,
pu2b8l0ic1 96re0l ations; Public Information Division, tr2a8ns0p1o2rt7;6 membranes, models, 2801463 rleevseelasr,c h,p ar2a8p0le3g6i8c0s;, o2p8h0t2h9a1l9m;i c ocsuollaurt iomnisn,i discs,
publications; American Journal of Hospital tryptophan; adverse reactions, dermal mucinosis, stability, storage, 2806032; release, crosslinked
2Ph8a0r0m2a8c2y , 2801561; Clinical Pharmacy, 2my8a0l5g7i9a4 ; sycnodnrtaommien,a ti2o8n0,4 66t3o;x icittoyx,i cietoys,i nophilia- spoolluytmioenr cmaastsreitcteess,, 22880024128253;; tsetaarb ilciotyn,c enItVr ations,
role; technicians, current objectives, 2800277 eosinophilia, therapy, 2804719; toxicity, MICs, 2802923
standards; primary care pharmacy practice, eosinophilia-myalgia syndrome, lack, 2804056; infections; therapy, neutropenia, 2802697
residency programs, 2800264 toxicity, eosinophilia-myalgia syndrome, interactions; nonsteroidal anti-inflammatory
strategic planning; reports, 1990-91, 2800014 manufacturing process, 2801042; toxicity, agents, 2804750
te2c8hn0i5c7i0a8n s; pharmacy, recommendations, etohesrianpoyp,h il2i8a0-1m2y1a4l;g iat oxsicyintdyr, omeeo,s inoocpthrieloitaid-em yalgia ka2n8a0m2y0c6i5n;; raesnids tcanecfet,a ziEd.i mceo,l i,m epleidoiiadtorsiciss, therapy,
Americans with Disabilities Act; pharmacy, syndrome, U.S., 2801097; toxicity, 2800210
community; issues, 2802959 eosinophilia-myalgia syndrome, 2800057, kanamycin sulfate; release, crosslinked polymer
Amethocaine, see Tetracaine 2800074, 2801113, 2801114, 2801119, matrices, 2802185
Amifloxacin 2804664; withdrawal, depression relapse, methodology; dosage, geriatrics, 2800855
chromatography, liquid; plasma, urine, dogs, rats, 2802665 monitoring; pharmacy service, quality assurance,
monkeys, 2803781 Amino Optic-C, see Ascorbic acid 2801086; programs, 2800382, 2800452
comparison, sulfamethoxazole, combination, Aminoaciduria; vigabatrin, effects, 2804236 neomycin; topical preparations, in vitro
t2r8i0m2e0t4h2o prim; urinary tract infection therapy, 3-2A8m0i0n1o8-82 -arylamin 0 | synthesis, neatnitlimbiaccitne;r iaaln de fcfeicptrso,f lo2x8a0c3in3,5 6 peritonitis therapy,
pharmacokinetics; dosage, 2802893; geriatrics, Aminoavarones; synthesis; antibacterial, cytotoxic CAPD, 2802090; dosage, kidney failure,
2802330 effects, 2801836 models, 2805608; interactions, piperacillin,
Amikacin Aminobenzoic acid; concomitant therapy, 2804110 pharmacokinetics, hemodialysis, 2801667; once
and cefotaxime or ceftazidime; septicemia, Aminocaproic acid; prophylaxis; bleeding, vs thrice daily, 2802706
meningitis therapy, 2802690 induction chemotherapy, Jehovah’s Witness, pharmacokinetics; AIDS, 2800817; dosage,
and ceftazidime or cilastatin sodium, 2801994 obesity, 2800818; monitoring, hospitals,
combination, imipenem; infection therapy, Amino-a-carbolines; chromatography, liquid; 2803497; neonates, review, 2806260
2804122 cigarette smoke, 2803302 prescribing; evaluations, 2800619
blood levels; circadian rhythm, 2804968 Amino-y-carbolines; tae liquid; resistance; Shigella, Korean hospitals, 2803869
ciprofloxacin, ethambutol and rifampin; cigarette smoke, 280330 streptomycin; albumin microspheres, distribution,
Mycobacterium infections therapy, AIDS, ee eee -L-alanyl-L- rats, 2804178; resistance, E. coli, pediatrics,
2801195 proline, see AB-4 2800210
dosage; pharmacokinetics, bactericidal activity, 4- Amino:S-chloro-N- 1-ethylimidazolin-2-yl)- streptomycin sulfate; and doxycycline, brucellosis
2802333 methyl]-2 chromatography, therapy, 2802119; IV, pulmonary tuberculosis
dosage schedules; preterm infants, 2801420 liquid; pharmacokinetics, 2802869 therapy, 2805913
pharmacokinetics; hematologic neoplasms, 4-Amino-5 ,6-dihydro-3-phenyl-2H- therapy, 2804141; review, 2803224
2802325; predictions, Koreans, 2804423; 1}b [5,4-b]pyran-2-ones; synthesis; tobramycin; and ciprofloxacin, toxicity, lobar
predictions, Lotus 1-2-3, 2800868 locala nesthetic, cardiac effects, 2801842 pneumonia, superinfection, 2805825; and
prescribing; hospitals, Spain, 2802710 5-(B les; synthesis; penicillin G, C. xerosis endocarditis, 2802704;
resistance; urinary tract infections, 2801640 Paar effects, rats, 2804924 and piperacillin, P. aeruginosa, AIDS, 2805316;
Amikacin sulfate; pharmacokinetics; spinal cord Aminoglycosi blood levels, gravity flow vs infusion pumps,
injuries, models, 2804979 amikacin; and cefotaxime or ceftazidime, 2801853; endotracheal, pneumonia therapy,
Amikin, see Amikacin sulfate 2802690; and ceftazidime or cilastatin- 2801258; interactions, ceftazidime,
Amiloride imipenem, 2804122; blood levels, circadian pharmacokinetics, 2802744; interactions,
a liquid; and analogs, plasma, rhythm, 2804968; combined therapy, piperacillin, pharmacokinetics, hemodialysis,
rats, 280381 Mycobacterium infections, AIDS, 2801195; 2801667; tear concentrations, MICs, 2802923
combination, spdvechoeotaliatie comparison, dosage, pharmacokinetics, bactericidal activity, tobramycin sulfate; ciprofloxacin and
perindopril, 2804685; vs indomethacin- 2802333; dosage schedules, preterm infants, erythromycin, therapy, 2802077; interactions,
hydrochlorothiazide, diabetes insipidus, 2801420; pharmacokinetic predictions, Koreans, cephalosporins, blood levels, lack, 2805944;
pediatrics, 2802648 2804423; pharmacokinetics, hematologic ophthalmic solutions, stability, storage, 2806032
diabetes insipidus; therapy, lack, foscarnet neoplasms, 2802325; prescribing, hospitals, toxicity; kidney, DUR, 2805815
adverse reactions, 2801093 Spain, 2802710; resistance, urinary tract 4-Amino-5-hexenoic acid, see Vigabatrin
Amines infections, 2801640 p-Aminohippurate, see Aminohippuric acid
permeation; skin, drugs, enhancers, 2802753 amikacin sulfate; pharmacokinetics, spinal cord Aminohippuric acid
titrimetry; dosage forms, 2803340 injuries, 2804979 excretion; urine pH, moment analysis, 2804969
International Pharmaceutical Abstracts 1223
Aminohippuric acid Subject Index
transport; kidney failure, 2804990 Amobarbital N-glucosides; excretion; a wasting, triamterene therapy,
3-Amino-2-hydrazino-4(3H)-quinazolinones; diastereoisomers, 2806245 00704
synthesis, 2800188 Amobarbital sodium; metabolism; utilization; therapy, toxicity, 2805332
9-Amino-7-methoxy-1,2,3,4-tetrahydroacridine; diastereoisomers, excretion, 2806245 Ampicillin
effects; parasympathomimetic, 2802840 Amodiaquine analysis; flow injection, 2804960
Amino-2-oxazolines; synthesis; X-ray malaria; therapy, review, 2802835 and mezlocillin; therapy, premature labor,
crystallography, 2804922 toxicity; relation, dosage schedules, metabolism, 2803098
. see Aminopyrine 2806248 blood levels; pharmacokinetics, LC, 2803867
Aminophylline Amono, see Indomethacin chromatography, liquid; serum, urine, 2805537
absorption; dog models, methodology, 2801894 Amoxapine; and alprazolam or clonazepam; panic combination, sulbactam; alveolar lining fluid
adverse reactions; ¢ sy disorder therapy, 2805295 levels, 2802894; cost benefit analysis, 2800859;
theophylline overdose, 2803507 Amoxicillin therapy, cost savings, 2800490
asthma; acute, therapy, 2804251; therapy, alone and with clavulanic acid; susceptibility, dosage; intrathecal, preparation guidelines,
2804252 Bacteroides, Fusobacterium species, 2802349 3490
blood levels; monitoring, pediatrics, hospitals, analysis; flow injection, dosage forms, 2803326 endometritis; prophylaxis, cesarean section,
2804100 and probenecid; comparison, cefixime, gonorrhea review, 2804701
concomitant therapy, 2802588 therapy, 2801264; vs doxycycline, erythema meningitis; aseptic, therapy, infants, 2802554,
effects; pulmonary function, age, 2801777 chronicum migrans therapy, 2805278 pneumococcal, therapy, 2800124; therapy, CSF
excretion; TPN effects, geriatrics, 2805958 combination, clavulanate potassium; comparison, bacterial counts, 2801440
incompatibilities; ceftazidime, 2800722; cephradine, UTI therapy, 2803100 pharmacokinetics; effects, parenteral nutrition,
cefuroxime injections, 2800736 combination, clavulanic acid; effects, 2803647
intravenous; theophylline blood levels, 2805345 Enterobacteriaceae, in vitro, 2802351; effects, prophylaxis; cesarean section, 2801238; preterm
lung diseases; systemic urticarial vasculitis, lack, bird fancier’s lung, misdiagnosis, delivery, cervix incompetence, 2805935
2801247 2800111; review, 2802824 resistance; E. coli, pediatrics, 2800210; S. typhi,
status asthmaticus; therapy, 2802215 comparison, cefpodoxime proxetil; urinary tract 2801445; urinary tract infections, 2801640
sustained-action; tablets, equivalency, 2804762 infections therapy, 28 stability; suppositories, bases, storage, 2804812
therapy; dipyridamole toxicity, 2805427 concomitant therapy, 2802588 Ampicillin anhydrous, see Ampicillin
toxicity; seizures, effects, ephedrine, Lyme disease; therapy, 2804852 Ampicillin embonate; dissolution rates; LC, pH
hydrocortisone, rats, 2804746 malabsorption syndromes; effects, growth, effects, 2803162
Aminopyrine; ss complexes, B- pediatrics, lack, 2802635 Ampicillin sodium
cyclodextrin, 2803730 otitis media; with respiratory virus infection, combination, sulbactam sodium; anaerobic
2-Aminopyrrole-3,4-dicarboxylic acid diamides; pediatrics, 2801233 isolates, 2802924; comparison, clindamycin-
synthesis, 2806192 prophylaxis; preterm delivery, cervix gentamicin, costs, 2801512; IV, liver abscess
4-Aminoquinolines; synthesis; positive inotropic incompetence, 2805935 therapy, 2802630
effects, in vitro, 2804916 therapy; patient consultation, 2806102 interactions; parenteral nutrition,
7-Aminoquinolines; effects; antiviral, herpesvirus xicillin embonate; dissolution rates; LC, pH pharmacokinetics, 2803647
hominis, 2806274 effects, 2803162 stability; suppositories, bases, storage, 2804812
Aminosalicylates; gastrointestinal diseases; lower Amoxicillin trihydrate Ampuls
bowel, therapy, 2806119 combination, clavulanate potassium; comparison, diethylstilbestrol diphosphate; direct injection
5-Aminosalicylic acid, see Mesalamine cefaclor, bronchitis therapy, 2803608; lactation, analysis, 2805555
Aminosyn II 2804982; oral, liver abscess therapy, 2802630 glass; splinters, 2803050
dextrose and fat emulsions; stability, storage, dosage schedules; pyelonephritis, 2803120 injections; titrimetry, equipment, 2803824
containers, 2802189 Amoxycillin, see Amoxicillin packaging; pharmaceutical industry, equipment,
TPN formulations, stability, automated Amoxycillin embonate, see Amoxicillin 2805163
compounding methods, 2805412 embonate standards; injection containers, 2803467
9-Amino-1,2,3,4-tetrahydroacridine, see Tacrine Amperometry; drugs; a, biological sterility; tests, lyophilized drugs, 2803478
3-Amino-thieno-[2,3-b]p 2-carboxamides; samples, review, 2805546 tilidine; TLC, 2804946
3-sAynmtihnesoixsy; -(aEnt)i--2al-lmeergtihco xeyffiemcitsn,o prratosp, io2n8y0!5 523 ‘(a+)i-p Ahmepthameitna- emsi ne, see Dextroamphetamine Amqurailnitoyn ea ssluarcatnactee; purtoiglirzaamtsio,n ; 28re0v2i0e5w1, criteria,
monobactams; synthesis; antimicrobial effects, abuse; administration routes, toxicity, 2801147; Amsacrine
lack, 2805510 athletes, Italy, survey, 2805083; intravenous, incompatibilities; injections, stability, 2802191
minoxypropionyl monobactams; synthesis; mucormycosis brain abscess, 2802717; patterns, neoplasms; therapy, review, 2804861
antimicrobial effects, lack, 2805510 toxicity, 2804668; pharmacy students, survey, m-AMSA, see Amsacrine
Amiodarone 2805673; pregnancy, toxicity, 2805808; urine Amylobarbitone, see Amobarbital
arrhythmia; therapy, 2806085; therapy, review, levels, pregnancy, 2803410 Amyloidosis
2804297 obesity; therapy, 2804877 cyclophosphamide; alone and with prednisolone,
catorniaclo mfiitbarinltl attiohne;r aptyh,e ra2p8y0, 5129860 2681 pAmepsh otericinrs , ” Amphotericin B metlhperhaaplya,n 2a8n0d2 1p1r4e dnisone; therapy, 2801265
effects; dyspepsia, 2801633 acquired immunodeficiency syndrome; therapy, prednisolone and cyclophosphamide; therapy,
interactions; phenytoin, toxicity, 2802748; home care, 2803741 2802114
theophylline, blood levels, 2805947 administration rate; IV infusion, toxicity, prednisone and melphalan; therapy, 2801265
monitoring; parameters, evaluations, 2804020 2804064 Amyris oil; oils, essential; analysis, 2802773
toxicity; thyroid hormone function, 2806122 administration routes; intranasal, absorption, Anabolic agents
Amiodarone hydrochloride; interactions; pediatrics, 2800845 athletes; drug abuse, toxicity, 2804241
levothyroxine, increased thyroid stimulating adverse reactions; red man syndrome, 2800042 biochemistry; therapy, 2802833
hormone, hypothyroidism, 2804156 and flucytosine; cryptococcal meningitis therapy, nandrolone decanoate; nitrogen metabolism
Amiprilose hydrochloride; structure; 2804704; cryptococcosis therapy, 2805896 effects, trauma patients, 2804136
nuidiaaiaary, 2802268 candidiasis; liver, therapy, 2800664; therapy, steroids; abuse, athletes, Italy, survey, 2805083;
Amitriptyline fluconazole resistance, 2805268 abuse, lack, psychological effects, athletes,
clinical studies; methodology, review, 2804448 concomitant therapy, 2802325 2801106; toxicity, cardiac, lipid effects,
concomitant therapy, 2802597 dosage forms; liposomes, lipids, detergents, 2805804
metabolism; LC, urine, 2803814 2802771 therapy; and abuse, toxicity, legislation, 2803732
Stability; kinetics, 2806045 filtration; pore size, 2800303 Anafranil, see Clomipramine hydrochloride
Amitriptyline hydrochloride fluconazole and flucytosine; T. beigelii Analeptics, see Central nervous system
combination, chlordiazepoxide; GLC, tablets, meningitis, 2802705 stimulants
2804951 incompatibilities; dextrose, stability, 2800720; Analgesics and antipyretics
pharmacokinetics; blood, brain levels, rats, dextrose, stability, high concentration, 2804802; abuse; geriatrics, 2804505
2804988 enalaprilat, IV injections, 2802192; foscarnet, acetaminophen; absorption, interactions, atropine,
Amlexanox; comparison, cromolyn sodium, HSR- IV injections, 2800163 2802205; abuse, lod
6071, ketotifen; allergic asthma, rats, guinea interactions; pentamidine, toxicity, 2802162 2801135; beads, dissolution rates,
pigs, 2802857 lung abscess; intrapleural administration, 2800661 spheronization techniques, 2800006; blood
; effects; relation, blood levels, age, mechanism of action; dosage forms, 2801373 levels, saliva levels, 2804420; compaction,
2804976 meningitis; cryptococcal, therapy, 2803643 models, methodology, 2805035; comparison,
Ammonium chloride; alkalosis; metabolic, mucormycosis; brain abscess, therapy, 2802717 bromfenac sodium, postoperative pain therapy,
therapy, 2806150 pharmacokinetics; low birth weight infants, 2802037; comparison, oxindanac anti-edematous
Ammonium lactate; comparison, RWS 1-14; dry 2801415 effects, 2802050; complexes, cyclodextrins,
skin therapy, 2803549 prescribing; hospitals, Spain, 2802710 humidity, stability, 2805401; dissolution, in
Amnesia; diazepam; toxicity, IV bolus, 2801989 therapy; fungal infections, neutropenic patients, vitro-in vivo, tablets, 2801290; distribution
Amniocentesis; methylene blue; toxicity, intestinal 2805292; T. glabrata, fluconazole resistant, systems, hospital pharmacy, 2804623; effects,
obstruction, infants, 2802562 2800680 Gilbert’s disease, impaired hepatic elimination,
Amobarbital; suspensions; dispersion, particle toxicity; kidney, sodium loading prophylaxis, 2801758; effects, PGE synthesis, 2801786;
size, 2801695 2804099; pentoxifylline prophylaxis, 2800679; gastric emptying rate, menstrual cycle effects,
1224 International Pharmaceutical Abstracts